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1. INTRODUCTION 
 
The multimodality treatment arsenal for head and neck squamous cell carcinoma has 
been recently supplemented by transoral robotic surgery (TORS) [1]. It is a novel 
method to decrease treatment-related morbidity while maintaining comparable 
oncological results to conventional surgery and to primary chemoradiation therapy. 
TORS has been approved by the United States Food and Drug Administration (FDA) 
for T1 and T2 malignancies of the upper aerodigestive tract in December 2009. Since 
then, the transoral application of the daVinci Surgical System (Intuitive Surgical, Inc., 
Sunnyvale CA, USA) has considerably spread in Europe as well [2]. 
 
1.1. Background 
 
TORS has become well established in recent years, and is used mostly for the resection 
of oropharyngeal as well as of select hypopharyngeal and supraglottic tumours.It is 
interesting to note that the sudden shift towards first-line TORS in the U.S. has occurred 
despite preceding decades of declining utilization of surgery in favor of primary chemo-
radiation therapy (CRT) across the majority of U.S. head and neck cancer centers. The 
explanation for the rapid acceptance and implementation of first-line TORS therapy in 
the U.S. is threefold. Most importantly, mounting skepticism – especially among head 
and neck surgeons – as to the net benefit of first-line CRT in terms of overall survival 
(OS) and quality of life (QOL) in comparison to first-line definitive surgery for head 
and neck squamous cell carcinoma (HNSCC) has provided the impetus towards a shift 
to the latter [3]. In Table 1., we listed the percutaneous endoscopic gastrostomy (PEG)-
dependency data of three recent studies [4-6]to compare functional (swallowing) 
outcomes of primary 3D conformal radiotherapy (RT) with chemotherapy [4], primary 
intensity modulated radiotherapy (IMRT) with chemotherapy [4], transoral laser 
microsurgery (TOLM) [5]  and TORS [6] for oropharyngeal cancer. 
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Table 1. 
Comparison of primary chemoradiotherapy, transoral laser microsurgery (TOLM) and 
transoral robotic surgery (TORS) with regards to PEG-dependency 
 
 
 
Abbreviations: 
PEG: percutaneous endoscopic gastrostomy 
3D conformal RT+CT: three-dimensional conformal radiotherapy with chemotherapy 
IMRT+CT: intensity modulated radiotherapy with chemotherapy 
TORS: trans oral robotic surgery 
TOLM: trans oral laser microsurgery 
 
The sudden change in HNSCC demographics – from older patients with a long history 
of tobacco and alcohol abuse to younger patients without substance abuse issues – due 
to the human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) 
epidemic[7-10] has only served to compound the skepticism surrounding the benefits of 
first-line CRT use [11]. The long-term effects of primary CRT versus first-line surgery 
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on QOL and OS must be carefully considered in this new patient demographic, whose 
life expectancy is decades longer than the traditional HNSCC patient [12, 13]. 
 
Second, the widespread use of first-line CRT over the past several decades in the U.S. 
inevitably led to the graduation of successive cohorts of head and neck surgeons with 
little experience in performing open procedures for such cancers. Third, the failure of 
trans-oral laser microsurgery (TOLM) to gain truly widespread popularity in the U.S. 
provided fertile grounds on which a novel minimally invasive technique could take hold 
[3]. 
By contrast, a different situation exists in continental Europe with regards to the 
preferred first-line treatment for OPC, hypopharyngeal and supraglottic cancer. 
Although primary CRT plays a significant role in the management of such tumors, first-
line surgery has remained a popular option here. TOLM was incorporated into most 
head and neck training programs, with open resections for such cancers remaining a 
viable treatment option. This situation has not changed in the face of the HPV-epidemic, 
which has also struck Europe,[10] with many head and neck surgeons (especially in 
Germany and France) still favoring surgery in such cases, whether it consists of TOLM, 
partial laryngeal framework surgery, lateral pharyngotomy or open resection with a lip 
split or mandible split. 
 
Before the advent of robotic surgery and the HPV epidemic, proponents of first-line 
CRT for T1-T2 pharyngeal and laryngeal carcinomas in centers where TOLM was not 
popularized had strong arguments for its use. The operative risk and morbidity 
associated with an open procedure remains a compelling argument against surgery, 
especially for the classic HNSCC patient with systemic co-morbidities associated with 
decades of substance abuse. However, the increasingly younger patient demographic 
combined with the novel minimally invasive approach offered by TORS is tipping the 
scale back towards definitive surgery across the U.S. as well. 
 
The low morbidity trans-oral access offered by TORS has not generally been 
recognized as a completely novel approach in Europe, where TOLM has been widely 
accepted and used for decades.  Despite the introduction of TORS and the accessibility 
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of the daVinci Surgical System in most academic centers, TOLM remains a gold 
standard treatment option for first-line management of pharyngeal and laryngeal tumors 
across many European centers. By comparison, in the U.S. – where oncologic TOLM 
has not been as widely popular as in continental Europe and reported data has been 
mainly restricted to some high-volume centers [5, 14, 15] – TORS is now generally 
considered the preferred trans-oral surgical modality for such tumors. In addition to a 
quicker learning curve [16], the TORS approach features other important advantages 
over TOLM that will be discussed. With proper patient selection, the advantages of 
TORS present strong arguments for its first-line use in place of CRT in the U.S. and in 
place of TOLM in Europe. 
 
1.2. TORS for Oropharyngeal Squamous Cell Carcinoma (OPSCC) 
 
TORS, as a surgical tool, has some great advantages over conventional open surgery 
[17] and over the tangentionally cutting traditional transoral laser microsurgery, those 
being low-morbid surgical access (vs. open surgery through a lip split, mandible-split or 
lateral pharyngotomy) under excellent 3D-HD visualisation and en bloc, multi-planar 
manual margin control (vs. transoral laser surgery) as the most important TORS-
features and selling points [18]. However, most patients eligible for TORS could be 
potentially treated with primary chemoradiation as well [19], with comparable 
oncological outcomes. 
 
Unlike most publications on primary chemo-radiotherapy with good results for 
oropharyngeal cancer, our oropharyngeal TORS-population includes only 34% HPV-
positive patients, which may make direct comparisons difficult. The main question here 
to ask when considering TORS is whether the treatment-related morbidity of TORS, 
combined with the added morbidity of the potentially still necessary adjuvant therapy, is 
lower than the morbidity of primary chemoradiation [20][21]. 
 
There is Level 2c evidence in the literature [13] showing that early oropharyngeal 
cancer can be treated with surgery alone with high long-term quality of life. Long-term 
survivors of oropharyngeal cancer benefit from complete surgical resection, as 
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surgically treated patients complain significantly less about dry mouth and dental 
problems, compared to patients treated with primary chemo-radiation. Primary surgery 
with postoperative radiotherapy in selected patients with limited primary tumours and 
advanced neck disease renders excellent quality of life [13, 22]. 
 
In our study, we summarize and evaluate our initial experiences with oncological TORS 
procedures, based upon the prospectively collected clinico-pathological data of our first 
35 TORS-patients with oropharyngeal cancer. 
 
1.3. TORS for Hypopharyngeal Squamous Cell Carcinoma (HPSCC) 
 
While most published TORS-data focus on the oropharynx and a new paradigm shift is 
being witnessed regarding the primary treatment of HPV-driven oropharyngeal cancer, 
there has been much less attention paid to the hypopharyngeal application of TORS so 
far. Nevertheless, TORS provides with definitive advantages [23, 24] over the 
tangentionally cutting traditional transoral laser microsurgery (TOLM) in the 
supraglottic region and in the hypopharynx, those being excellent 3D-HD visualisation 
with a great depth of field and en bloc, multi-planar manual margin control, avoiding 
piece-meal resections. Its benefits, however, are most obvious when the patient does not 
need adjuvant therapy. Therefore, appropriate patient selection is of paramount 
importance [18, 25]. 
 
1.4. The Appropriate Neck Dissection for Patients Undergoing TORS 
 
In surgical oncology, there is evidence that the overall number of harvested regional 
lymph nodes, also known as the nodal yield of regional lymphadenectomies, is an 
independent prognostic factor in colon [26, 27], colorectal [28], bladder [29-31], 
prostate [32], penile [33], esophageal [34], gastric [35] and breast cancer [36]. This is 
applicable even to node negative cases, i.e. irrespective of the metastatic involvement of 
the removed lymph nodes [37]. 
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In head and neck cancer, the same has been shown in papillary thyroid [38, 39], and 
squamous cell cancer of the oral cavity [37, 40-43], the oropharynx [42] and the 
hypopharynx [42, 44]. A recent international multicenter analysis of pooled individual 
patient data confirmed that nodal yield is a robust independent prognostic factor in 
patients undergoing selective neck dissection (SND) for cN0 oral squamous cell cancer 
(OSCC) [43]. 
 
Further, nodal yield may be a useful parameter for the quality assessment and for the 
accountability of surgical treatments, where standardisation of surgical technique will 
be necessary to allow reproducibility and statistical comparison of surgical and non-
surgical therapeutic options. 
 
In this study, having accepted the oncological importance of nodal yield described by 
other authors as listed above, our aim was to show how this independent prognostic 
factor can be influenced by the applied surgical concept and dissection technique. This 
is the first paper in the head and neck cancer literature to show a statistically significant 
nodal yield advantage correlated to a certain surgical technique. 
 
Several factors have an influence on nodal yield. First, individual patient anatomy is 
variable and the total number of „available“ lymph nodes in a specific patient is 
unknown [45]. However, cadaver data suggest that there are at least a total of 30-40 
lymph nodes in Levels I-V on one side of the neck in average [46]. Second, the surgeon 
should remove as many lymph nodes from the relevant neck levels as possible [47], in 
order to bring the harvested lymph node count as close to the (otherwise unknown) 
available lymph node count as possible. Finally, the thoroughness of the 
histopathological workup has a significant impact on the documented lymph node count, 
presented by the pathologist [48]. The latter is the only information we may learn and 
use as the basis of our clinical decision management, while each step is likely to 
represent a certain data loss. 
 
Although therapeutic decisions (e.g. offering or omitting adjuvant treatment) can only 
rely on the staging based on the documented lymph node count, the course of the 
DOI:10.14753/SE.2015.1766
 12 
disease and ultimately the patients‟ life is affected by the harvested lymph node count. 
Even if a removed, clinically negative, but in reality micrometastatic node is missed by 
the pathologist and goes unnoticed [37], that specific involved node has already been 
removed from the patient, so they are more likely to stay disease free irrespective of the 
documented, possibly incorrectly pN0-staged neck [37]. 
 
1.4.1. Cultural and Historical Backgroundof ND Techniques 
 
What we later in this paper refer to as the fascia unwrapping or horizontal technique, 
was first described by Osvaldo Suarez and popularized in the Latin world in the 1960s, 
based on his concept of the then-so-called functional neck dissection (not to be confused 
either with the selective or with the modified radical neck dissection, as it will be 
detailed later in this text). 
 
Suarez published his works in Spanish. As his papers have been translated into English 
during the 1970s and 1980s, North-American and British surgeons started to teach this 
technique to a much broader audience in the United States and in the countries of the 
Commonwealth from the 1990s, thanks to the clinical fellowship-based training system 
of the English-speaking world. 
 
By the 1990s and 2000s, as a result of this cultural cross-fertilization, the fascia 
unwrapping or horizontal technique has become the predominant dissection method 
when doing selective neck dissections in the United States and in the entire 
Commonwealth. In these countries, this technique today is the state of the art, without 
even having a specific name: this is the way selective neck dissections are done by 
default. 
 
In continental Europe, however, selective neck dissections are, conceptually, still 
mostly seen as further modifications of the modified radical neck dissection, not as an 
entirely different functional concept, but as further derivatives of the original radical 
concept of George Crile from 1906. The latter has been typically performed in a 
vertical, i.e. caudal to cranial or cranial to caudal fashion. Thus, the selective neck 
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dissection kept this dissection principle in continental Europe, especially among 
maxillofacial surgeons but also in the case of many otolaryngologists, having only 
sporadically been influenced by the British-American-Australasian clinical fellowship 
training programmes. 
 
1.4.2. Timing of Neck Dissection in TORS Patients 
 
Transoral robotic surgery (TORS) for T1 and T2 head and neck squamous cell 
carcinoma (HNSCC) has become an established primary treatment option in the 
oropharynx, hypopharynx and supraglottic larynx in Europe [2, 6, 25] and worldwide 
[1, 18, 23, 49-51]. The surgical treatment of oropharyngeal, hypopharyngeal and 
laryngeal cancer frequently includes the appropriate regional lymphadenectomy of the 
neck, also known as neck dissection (ND). However, the ideal timing of neck dissection 
in TORS-patients remains controversial, where the priority of the assumed oncological 
advantages of a concurrent procedure is often challenged by obvious time constraints, 
especially in Europe, where the robot is available for most head and neck departments 
only in limited time slots weekly or even fortnightly. 
 
Besides the low level evidence in the literature [52-54] regarding the best timing of 
neck dissection for patients undergoing TORS for their primary disease, there are some 
common sense considerations about the advantages and disadvantages of concurrent 
and staged neck dissections in this context. 
 
Performing the neck dissection in the same general anaesthesia as the TORS procedure 
(concurrent ND) may provide with some benefits. As the definitive treatment for the 
primary tumour and for the neck lymph nodes can be done in a single session, it is more 
convenient for the patient, may reduce the overall anaesthetic risk of the procedure, the 
hospitalization time, and the associated costs as well. Furher, the concurrent ND would 
incur no delay in patient progress towards a possibly necessary adjuvant therapy. 
Another argument is the option for vessel ligation during the neck dissection to prevent 
postoperative bleeding from the primary TORS-resection site, upon the surgeon‟s 
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preference [1], and the possibility to conveniently include an elective, temporary 
tracheotomy into the neck incision, should the latter be necessary for airway safety. 
 
In contrast, the staged neck dissection, i.e. a ND performed in a time interval after the 
primary tumour resection, may have some other advantages. These include a possibly 
less frequent intraoperative pharyngocervical fistula formation, more convenient theatre 
list planning – including the distribution of robotic slots among the involved 
departments –, the opportunity to address close or positive resection margins reported in 
the final histopathology after TORS, and the possiblity to close a tracheotomy if it was 
done during the TORS-procedure previously. A delayed neck dissection may even 
prevent an elective tracheotomy during the primary TORS-session, by reducing 
laryngopharyngeal mucosal swelling due to the untouched outer neck. 
 
This issue is well known to the European TORS-community. Our team, as one of the 
most experienced TORS-units in Europe with over a hundred robotic cases done in the 
past 3 years, is frequently being asked about our practice and experiences in this regard. 
At the beginning, our firm intention was to do all neck dissections on the same day, and 
we did so with our first 20-25 TORS-patients. With two robotic cases on the same list, 
some of them requiring bilateral neck dissections, this practice stretched the limits of 
our scrub nurses and the anaesthesia team, especially at the beginning of our robotic 
learning curve when patient turnover, patient positioning, docking the robot and robotic 
console work took much longer time than it does today. For this reason, we changed our 
practice and started to do the neck dissections in a timely staged fashion. The purpose of 
the present study was to provide our institutional experience on the safety and efficacy 
of staged versus concurrent ND, with special regards to intraoperative pharyngocervical 
fistula rate, postoperative complications and number of harvested lymph nodes. 
 
 
 
 
 
 
DOI:10.14753/SE.2015.1766
 15 
2. OBJECTIVES 
 
2.1. Oncologic Value of TORS for HNSCC 
 
The goal of this work was to assess the feasibility, resection margins, safety and 
oncological value of TORS in patients with HNSCC. The main target population is 
represented by patients with T1 and T2 oropharyngeal, hypopharyngeal and supraglottic 
cancer, where primary chemoradiation or transoral laser surgery are feasible treatment 
options as well. The main purpose of transoral robotic surgery in these patients is to 
maintain oncologic safety while reducing treatment-related morbidity. 
 
2.2. Functional Value of TORS for HNSCC 
 
While maintaining oncological safety comparable to that of primary CRT or TOLM, our 
purpose was to achieve better postoperative swallowing function compared to primary 
CRT. Omitting or reducing adjuvant treatment after primary surgery is equally 
paramount. With better resection margin control, appropriately selected and surgically 
staged patients may avoid adjuvant treatment or at least reduce ajuvant radiation therapy 
by 10 Gy and omit the chemotherapy component. 
 
2.3. Perspectives, Future Directions 
 
The above trend is expected to further unfold in terms of keeping the number of 
treatment modalities at the minimum, without compromising oncologic safety, 
especially in HPV-driven tumours. In addition to omitting or reducing adjuvant therapy, 
even surgery alone may become more conservative as well. In the primary tumour sites 
of the upper aerodigestive tract, real-time mass spectrometry evaluation of the surgical 
margins from the combustion products of monopolar cautery, coupled with TORS, may 
avoid unnecessarily large resections.In the outer neck, hot spot guided sentinel level 
superselective neck dissections (HSG SL-SSND) in appropriately staged patients may 
reduce the extent of resection to levels II and III using radiotracer injection during the 
initial panendsocopy and SPECT-CT prior to the neck dissection. 
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3. METHODS 
 
3.1. Prospective Data Collection 
 
The following set of data was collected in a prospective manner for each patient 
underwent TORS at our institution: Case number, date of presentation, date of 
diagnosis, date of procedure, patient age at TORS, patient gender, cTNM-classification, 
pTNM-classification, overall tumor stage, tumor site, tumor side, p16-status, HPV-
DNA-status, smoking pack years, alcohol history, margin status, closest margin, neck 
dissection levels done, nodal yield of neck dissection, number and level of positive 
lymph nodes, presence of extracapsular spread (ECS), adjuvant therapy, dosis of 
radiation in Gray (Gy) if applicable, chemotherapy, post-operative bleeding, need of 
tracheotomy, days intubated, intensive care unit (ICU) days, intermediate care (IMC) 
days, nasogastric (NG) tube days, percutaneous endoscopic gastrostomy (PEG) tube 
days, speech function, swallowing function, duration of follow-up, recurrence, time to 
recurrence and site of recurrence if applicable, alive or dead, date of death if applicable, 
alive with or without disease, dead with or without disease, modality of salvage if 
applicable, among other data concerning the technical details of the robotic procedures, 
i.e. which Endowrist instruments, which optic, which retractor etc. were applied for 
each specific procedure. 
 
3.2. Clinical Pathway 
 
For initial presentation, the patients have been referred to the Otolaryngology 
Outpatient Clinic of our tertiary referral center either by a primary care physician or by 
a private ENT-specialist in town. After clinical examination, preoperative work-up 
consisted of a magnetic resonance imaging scan of the head and neck, computed 
tomography of the thorax and sonography of the abdomen. This was followed by an 
examination under anaesthesia (EUA), i.e. a panendoscopy with biopsies, resulting in 
the histological verification and tumor mapping of the disease. The panendoscopy was 
performed by the same surgeon using the same TORS-specific retractor [55] (Laryngeal 
Advanced Retractor System (LARS) by Fentex Medical, Neuhausen, Germany and/or 
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Feyh-Kastenbauer modified by Weinstein-O‟Malley (FK-WO) by Olympus-Gyrus 
ACMI-ENT, Bartlett TN, USA) as in the case of the robotic procedures, to be able to 
accurately assess accessibility with the robotic system, as an inherent part of the patient 
selection. 
 
Having all these results within two weeks after initial presentation, the patients were 
finally discussed in detail at the Multidisciplinary Head and Neck Tumor Board of our 
Comprehensive Cancer Centre, critically considering TORS among other adequate 
treatment options before having decided specifically for this modality. After having 
completed surgical treatment, results of the final histology were discussed again at the 
Tumor Board regarding adjuvant therapy [56][57][58]. After completion of therapy, all 
patients have had a three-monthly follow-up schedule. 
 
3.3. Patients with OPSCC 
 
3.3.1. Patient Selection 
 
Following the above pathway, thirty-five patients with appropriately staged 
oropharyngeal cancer were selected for our initial robotic surgery series (Table 2). They 
underwent TORS between September 2011 and April 2013 (19 months‟ timeframe) as 
the primary treatment modality along with an appropriate uni- or bilateral neck 
dissection, as indicated, providing the largest single-institution TORS-cohort to date in 
the German-speaking countries. 
 
These thirty-five patients with oropharyngeal cancer had the following T-classifications: 
Nineteen patients presented with a T1-disease and sixteen patients had T2-tumors, while 
the overall staging represented TNM stage I-II in 13 cases and TNM stage III-IV in 22 
cases. Our thirty-five patients with oropharyngeal primaries [59][51] included the 
following subsites: the base of tongue (n=14) [60], the tonsillo-lingual angle (n=5), the 
tonsil (n=13) [50] and the soft palate (n=3). 
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Table 2. 
Patient characteristics of our oropharyngeal TORS patients[6] 
 
 
3.3.2. TORS Procedure 
 
After obtaining informed consent, all TORS-procedures and neck dissections have been 
performed under general anaesthesia with a transoral intubation using a reinforced, 
metal-coated laser-tube both cuffs blocked with air, only to provide protection from the 
proximity of the monopolar dissection. The surgeries were performed consistently by 
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the same TORS-team, licensed according to the official daVinci-TORS-training 
pathway approved by Intuitive Surgical, Inc. [16]. 
 
Our team consists of a fellowship-trained consultant head and neck surgeon as the 
console surgeon (first author), specialist registrars as surgical assistants (second and 
third authors) and TORS-licensed scrub nurses, coordinated by a multidisciplinary 
expert head and neck oncologist, also trained in and licensed for transoral robotic 
surgery (senior author). Consistency in the anesthesia team has also been encouraged 
but not always achieved due to scheduling issues [61]. 
 
All patients have been operated using the following surgical equipment: Soft Spandex 
lip and buccal retractor (Ortho-Care, Saltaire, West Yorkshire, UK); exposure obtained 
either using the LARS- [55] or the FK-WO-retractor system (trade names described 
previously); daVinci Si Surgical System being docked from the right side of the patient 
approximately in a 30°-angle between the patient cart and the operation table, as well as 
5mm and 8mm-Endowrist instruments (Intuitive Surgical, Inc., Sunnyvale CA, USA). 
 
The Endowrist-instruments included 8mm and 5mm monopolar permanent cautery 
spatula, 8mm Maryland bipolar forceps, 5mm Maryland dissector, 8mm fenestrated 
bipolar forceps and 8mm monopolar scissors. For oropharyngeal resections, we 
preferred the combination of a 5mm monopolar spatula with a 8mm Maryland bipolar 
forceps in the tonsillar and tonsillo-lingual regions, because of the bipolar capability of 
the latter, and that of a 5mm monopolar spatula with a 8mm fenestrated bipolar forceps 
in the base of tongue, because of the better grip and traction  provided by the latter, an 
important feature when using monopolar cautery as the power instrument for cutting. A 
12mm stereo endoscopic camera was used in each case: a 0°-optic for tonsillar and soft 
palate resections, and a 30°-optic (looking upwards) for most base of tongue resections. 
 
All of our TORS-resections were performed using monopolar dissection. The power 
generator was used exclusively in coagulation mode (blue), also when cutting, as this 
waveform provides a lot less traumatic dissection, less collateral conducted heat, less 
bleeding as well as the resection margins can be more accurately assessed by the 
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pathologists. These observations are supported by our non-robotic surgical practice and 
by other expert head and neck surgeons as well. The electrocautery power settings 
ranged between 10 and 25 Watts, usually being set on 15-20W for bipolar and on 20-
25W for monopolar cautery. It is paramount to avoid higher energy settings when 
operating in the regions of the head and neck in order to avoid oedema and to reduce the 
risk of nerve injuries and postoperative bleeding [62]. If the effectivity of the dissection 
is insufficient, it is usually a matter of too little tissue traction rather than too low power 
settings. If this occurs, appropriate traction must be provided in first place, instead of 
increasing the power of the electrocautery. 
 
In order to avoid postoperative mucosal oedema and swelling, all TORS procedures are 
performed in a slightly tilted head up position, so that the head is at the highest point of 
the patient‟s body even with the neck extended. In addition to this, an i.v. single shot of 
250mg methyl-prednisolon is given twice intraoperatively: at the beginning of the 
robotic resection for the first time, and once again after having completed the resection. 
Following the procedure, a nasogastric tube is placed while the patient is still sleeping. 
Patients were kept intubated for one night at the intensive care unit (ICU) after TORS, 
to keep their blood pressure low in order to reduce the risk of postoperative bleeding 
and to let the steroids work to reduce postoperative oedema before extubation to prevent 
airway obstruction [63]. Extubation took place the following morning in the presence of 
the surgeon. With this standard procedure, we managed to reserve elective tracheotomy 
for very selected cases (3 out of 35 patients, 8.6%), whose estimated risk of airway 
issues and postoperative bleeding was significantly higher than usual. 
 
3.4. Patients with HPSCC 
 
3.4.1. Patient Selection 
 
Since September 2011, we have been conducting a prospective TORS-trial at our 
institution, which initial part included 50 patients with T1 and T2 malignancies of the 
upper aerodigestive tract [6]. Among them, five patients underwent TORS and 
concurrent selective neck dissection for early hypopharyngeal cancer. In the present 
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subset analysis, we summarize and evaluate their clinico-pathological data in order to 
determine whether TORS is a suitable first-line treatment for early hypopharyngeal 
squamous cell carcinoma. 
 
After initial presentation, clinical examination and appropriate radiological staging, a 
panendoscopy was performed in each case by the same surgeon using the same TORS-
specific retractor [55] (Laryngeal Advanced Retractor System (LARS) by Fentex 
Medical, Neuhausen, Germany and/or Feyh-Kastenbauer modified by Weinstein-
O‟Malley (FK-WO) by Olympus-Gyrus ACMI-ENT, Bartlett TN, USA) as in the case 
of the robotic procedures, to be able to accurately assess accessibility with the robotic 
system [63], as an integral part of the patient selection. In the present subgroup of 
patients, three tumours were restricted to the lateral wall and apex of the piriform sinus, 
while the medial wall of the piriform sinus and consequently the aryepiglottic fold was 
also infiltrated in two further cases. The patients‟ demographic data and tumour 
characteristics are listed in Table 3. 
 
Table 3. 
Patient characteristics of our hypopharyngeal TORS patients[25] 
 
 
Abbreviations: 
PF: piriform fossa 
AEF: aryepiglottic fold 
HPV: human papilloma virus 
p/y: pack years 
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3.4.2. TORS Procedure 
 
After obtaining informed consent, all TORS-procedures and neck dissections have been 
performed under general anaesthesia with a transoral intubation using a reinforced, 
metal-coated laser-tube both cuffs blocked with air, only to provide protection from the 
proximity of the monopolar dissection [61]. The surgeries were performed consistently 
by the same TORS-team [16], licensed according to the official daVinci-TORS-training 
pathway approved by Intuitive Surgical, Inc. Consistency in the anesthesia team has 
also been encouraged but not always achieved due to scheduling issues [61]. 
In each hypopharyngeal TORS-procedure, the Endowrist instrumentation consisted of a 
5mm monopolar permanent cautery spatula and a 5mm Maryland dissector. These 5mm 
instruments allow a significantly higher degree of freedom than the 8mm instruments 
do, which is especially beneficial in the hypopharyngeal and supraglottic resections in 
our experience. A 12mm stereo endoscopic camera was used in each case with its 30°-
optic looking upwards. The monopolar power generator was used in coagulation mode 
(blue), set as low as at 15 Watts, in order to avoid excessive conducted heat and 
oedema, as well as to allow accurate histological margin assessment. Surgical technique 
and outcomes are summarized in Table 4. 
 
Table 4.: Surgical outcomesof our hypopharyngeal TORS patients[25] 
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Abbreviations: 
ICU: intensive care unit 
IMC: intermediate care 
NG: nasogastric tube 
PEG: percutaneous endoscopic gastrostomy 
 
As the access to the tumour is of utmost importance, selection of the retractor blade 
must be individual and appropriate. Currently, there are two major retractor systems on 
the market, specifically designed for TORS: the Laryngeal Advanced Retractor System 
(LARS) by Fentex Medical [55], and the Feyh-Kastenbauer modified by Weinstein-
O‟Malley (FK-WO) by Olympus-Gyrus. The most commonly used blades of both 
systems are shown on Fig.1. When performing TORS in the hypopharynx, the working  
space is much more confined than it is in the oropharynx [64]. Therefore, proper 
selection of the blade has an even greater impact on the access. On Fig.1., the longest 
blades provide with the best access to the piriform fossa, specifically the ones marked 
here as FK-WO 5 and LARS 1 and 2. Other ones marked as FK-WO 1-4 and LARS 3-4 
are designed for the base of tongue. 
 
 
Fig.1: Several blades of the FK-WO and LARS retractor systems[25]photo by BBL 
From left to right: FK-WO 1, 2, 3 and 4 for the base of tongue, FK-WO 5 for the 
piriform fossa, LARS 1 and 2 for the piriform fossa, LARS 3 and 4 for the base of 
tongue. The longest and narrowest blades are best suitable for hypopharyngeal 
exposure. 
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3.5. The Appropriate Neck Dissection 
 
This is a single-institution, prospective study with internal control group (Level of 
evidence: 2A). Our primary objective was maximizing the nodal yield at the lowest 
possible morbidity. In practice, this translates into preserving all anatomical structures 
other than lympho-fatty tissue. On one hand, no structure is supposed to be sacrificed on 
the account of a higher nodal yield; on the other, preserving important structures should 
not compromise nodal yield [65]. 
 
To balance these two goals, we found that the original functional concept of Osvaldo 
Suárez, recently popularized by Javier Gavilan in his 2002 book „Functional and 
Selective Neck Dissection“ [66], is best suitable to fulfil both requirements 
simultaneously. It can be logically translated into basic surgical principles in a stepwise, 
standardised fashion, focusing on the functional anatomical dissection along the fascial 
planes as the oncological barriers in the neck. It is not difficult to learn, easy to 
standardise and it can be safely reproduced by any head and neck surgeon, if the 
concept is well understood [67]. 
 
3.5.1. Prospective Data Collection of All Neck Dissections 
 
In this spirit, we gradually implemented the fascia unwrapping technique at our 
department, prospectively collecting clinico-pathological data of our neck dissection 
patients from February 2011. Until March 2013 (26 months), a total of 150 eligible 
patients were included in this comparison, operated by the same surgical team, having 
undergone a total of 223 neck dissections (including 73 bilateral procedures). The 
patients were divided into two groups, non-randomised, in a stepwise fashion according 
to the learning curve of the team, in order to compare these two surgical techniques and 
their possible effect on nodal yield. 
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3.5.2. Patient Cohort 
 
Eighty-two patients underwent neck dissection with the standardised fascia unwrapping 
technique (Group 1, horizontal, subfascial dissection with „fascia unwrapping“), while 
68 patients were operated without specifically appreciating the fascial planes of the 
neck, dissecting in a caudal to cranial fashion (Group 2, vertical dissection), all 
performed by the same surgical team. The specimens were removed en bloc in both 
groups. Before handing them over to the pathology [68], they were divided into 
individual levels by the surgeon, allowing the pathologist to identify the level of origin 
for each part of the specimen. 
 
Neck dissection specimens were processed and evaluated likewise consistently by the 
same pathologists in a predetermined, standardised manner. The pathologists were not 
aware of which dissection technique was used in which case. Clinical and pathological 
staging, type of neck dissection, the extent of neck dissection in terms of neck levels 
included, gender, laterality, technique of neck dissection, total number of lymph nodes 
harvested, lymph node count per each level and lymph node ratio were recorded. 
 
3.5.3. Inclusion Criteria 
 
All neck dissections containing at least 3 levels in any given combination were 
included, both N0 and N+, as long as the latter did not show evidence of extracapsular 
spread (ECS), so that the fascial planes still could be respected. Distribution of N0 and 
N+ necks were equal in the two groups. Types of neck dissection included Levels I-III, 
Levels I-IV, Levels I-V, Levels II-IV and Levels II-V, according to their primary 
tumour sites. Primary sites included T1 and T2 oral cavity (Levels I-III, I-IV or 
comprehensive), T1 and T2 oropharynx (Levels II-IV, I-IV or comprehensive), T1, T2 
and T3 hypopharynx and larynx (Levels II-IV or comprehensive) squamous cell 
cancers. 
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3.5.4. Exclusion Criteria 
 
Patients with clinically or radiologically suspect extracapsular spread (ECS) were not 
included in this study, as they would not have been eligible for the fascia unwrapping 
technique. Patients with previous neck surgery and previous radiation therapy to the 
neck [65], including indications for salvage surgery, were also excluded.  
 
3.5.5. Surgical Oncology Concept 
 
The original functional concept of Osvaldo Suárez is best approached by understanding 
the fascial compartmentalization of the neck and its role as an oncological barrier [69]. 
The lympho-fatty system of the neck is contained within a fascial envelope, which may 
be removed (i.e. unwrapped) with its entire content without taking out other neck 
structures, allowing maximum nodal yield and minimum morbidity simultaneously. 
 
The surgical technique that made this possible, was initially referred to as functional 
neck dissection because it allowed a functional approach to the neck in head and neck 
cancer patients, in terms of the oncological function of the fascial planes. This is not to 
be confused with the function of the structures to preserve, such as the internal jugular 
vein, the spinal accessory nerve and the sternocleidomastoid muscle. The term 
functional refers solely to the oncological barrier function of the cervical fascia, and 
functional neck dissection is neither synonymous with the term selective neck dissection 
nor with modified radical neck dissection, in any regard [70]. 
 
Functional neck dissection represents a surgical concept with no implications regarding 
the extent of the surgery, i.e. the number of levels removed. It still can be either 
selective or comprehensive, i.e. functional and selective or functional and 
comprehensive neck dissection, in terms of what levels are removed. It also can be 
either elective or therapeutic, depending on the cN-classification from an indication 
point of view, e.g. an electively perfomed functional and selective neck dissection, or a 
therapeutically performed functional and comprehensive neck dissection. 
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3.5.6. Surgical Technique 
 
The quantitative goal of maximizing the nodal yield is to be achieved by means of the 
qualitative concept of functional neck dissection, let it be selective or comprehensive, 
elective or therapeutic in the same time. It is not about trying to spot just another couple 
of more lymph nodes: it is about elegantly and effortlessly removing all lymph nodes of 
the relevant fascial compartments en bloc, with no structural compromises. The 
principle is a qualitative approach, which turns out to be quantitatively rewarding, not as 
its goal, but as its natural and inherent consequence [71]. 
 
The surgical technique that derives from the concept of functional neck dissection, is 
what the authors call as the fascia unwrapping technique, in order to avoid further 
confusion around the widespread misinterpretation of the term functional neck 
dissection. Fascia unwrapping, and the entire neck dissection incorporating this 
technique, is typically performed horizontally, from lateral to medial on a broad front 
(Fig.2.), by dissecting all lympho-fatty tissue in the fascial envelope en bloc, under 
appropriate tissue traction (Fig.3.), until the anterior front of the internal jugular vein is 
reached between the posterior belly of the digastric muscle (cranial border) and the 
clavicle (caudal border). If this is done properly, the unwrapped fascia envelope will 
contain all relevantly located lymph nodes (Fig.4.). 
 
 
Fig.2: Dissecting the cervical fascia off the leading edge of the sternomastoid muscle 
horizontally, from lateral to medial on a broad front;photo by BBL 
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Fig.3: Unwrapping the cervical fascia and its lympho-fatty contents; photo by BBL 
 
 
Fig.4: Completion of unwrapping the fascia along the course of the internal jugular 
vein i.e. the carotid sheath;photo by BBL 
 
3.5.7. Statistical Methods 
 
A multilevel mixed-effects negative binomial regression model was used to compare the 
number of detected lymph nodes with either surgical technique. To adjust for the cluster 
structure of the patient, resulting from the different levels within both sides of one 
patient, the patient as such was included as a random effect. Surgical method, level, 
side, gender and type of neck dissection were considered as independent variables. 
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Moreover, all two-way-interactions and the three-way interaction of method, level and 
side were included and kept in the model if significant (backwards elimination 
procedure using likelihood ratio test). Adjusted means with 95% confidence interval 
(CI) are presented. All models present available case analyses. A two-tailed p-value 
<0.05 was considered statistically significant. All analyses were performed using 
STATA 13 (StataCorp. 2013). 
 
3.5.8. Management of the Neck in TORS Patients 
 
The majority of TORS candidates require either a staging (cN0) or therapeutic (cN+) 
neck dissection based on the high incidence of nodal spread of pharyngeal and 
supraglottic HNSCC. Important considerations in the management of the neck in TORS 
include the extent of neck dissection, the timing of the procedure, nodal yield and the 
need for post-operative adjuvant therapy. For the cN0 neck, a staging (elective) 
selective neck dissection (SND) should be performed. Based on work by O‟Brien et al, 
a SND of levels I-IV is also an option for therapeutic management of cN1 disease of the 
oropharynx and oral cavity.[72] 
 
The timing of the neck dissection is also of significant importance. One of the crucial 
advantages of TORS over open procedures is the significantly decreased risk of 
pharyngocutaenous fistula. Following TORS resection of larger T2 tumors, such 
advantage may be lost if concurrent neck dissection is performed resulting in 
communication with the pharynx. Furthermore, neck dissection adds considerable 
amount of surgical time the TORS procedure; in centers that have time-limited access to 
the daVinci Surgical System, this may prove problematic. For these reasons, we elect in 
most cases to perform a staged neck dissection 7-10 days following TORS resection of 
the primary. 
 
The decision regarding the need for adjuvant radiotherapy following neck dissection is 
dependent on the number of pathologically involved nodes. In the absence of ECE, 
adjuvant radiation may be avoided for pN0 and pN1 disease. For this reason, the 
concept of minimum required nodal yield in staging and therapeutic SND for cN0 and 
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cN1 disease, respectively, is of significant importance. The SND must harvest a 
sufficient number of lymph nodes in order to statistically represent the neck. To 
illustrate, omitting adjuvant therapy for a pN0 neck based on the identification of 20 
nodes in the pathologic specimen (0/20) is safer than doing so based on a pN0 where 
only 10 nodes (0/10) were removed. 
 
Discretion must be used whenever TORS is considered as first-line therapy in the 
presence of cN2 or cN3 disease. The benefit of first-line TORS in decreasing patient 
morbidity in comparison to primary CRT is not as much present  when post-operative 
adjuvant therapy cannot be significantly reduced. In the absence of ECE, most experts 
would advocate for 56-60 Gy of adjuvant RT without chemotherapy. In this instance, 
TORS is justified based on the avoidance of chemotherapy and a reduction in required 
RT by at least 10 Gy. In the presence of ECE and/or other adverse features, however, 
most experts advocate for 66 Gy of adjuvant RT with concurrent chemotherapy. 
Justification for the first-line use of TORS over CRT in these instances is therefore 
limited, unless future randomized trials demonstrate a survival advantage. 
 
Predicting ECE based on physical examination and imaging is often not straightforward 
[73]; however, there is an association between increasing nodal involvement and risk of 
ECE [74]. This is of special significance when considering TORS for HPV-driven 
tumors, where a small primary is often accompanied by disproportionally advanced 
nodal disease, which often demonstrates ECE. Although current treatment protocols do 
not take HPV into account, it is possible that ongoing de-escalation trials may result in 
reduced adjuvant therapy recommendations for HPV nodal disease with ECE in the 
future. In the present setting, another option is to use what current intensity-modulated 
radiotherapy (IMRT) techniques already allow [75] to “de-couple” the primary site and 
the neck, avoiding significant doses of RT to the central axis and pharyngeal 
constrictors after a T1/T2 primary is fully resected, while the neck is still treated 
maximally with CRT.  These would serve to justify the use of first-line surgical 
modalities in HPV-driven tumors even with advanced neck disease. 
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3.5.9. Timing of ND Related to the TORS Procedure 
 
In this comparison, a total of 41 patients were included with TORS as their primary 
treatment for HNSCC. Twenty-one patients were defined as the control group, 
consisting of those treated with a concurrent ND during the same session with TORS. 
The experimental group included 20 patients undergoing a timely staged ND with a 
median time interval of 8.40 days (range, 3-28 days) following their TORS procedure. 
The patients‟ demographic characteristics, distribution of their primary tumour sites and 
the pathological TNM staging in the control group as well as in the experimental group 
are detailed in Table 5. 
 
Data have been collected in a prospective manner from November 2011 to April 2013 at 
the Department of Otorhinolaryngology, Head & Neck Surgery and Oncology of the 
University Medical Center Hamburg-Eppendorf, Hamburg, Germany. The purpose of 
the data collection was to identify the incidence of pharyngocervical communication 
during the operative procedure as well as that of the postoperative pharyngocutaneous 
fistula formation, bleeding from the primary resection site and from the neck dissection 
site, neck hematoma, seroma and infection. Surgical outcome measures included the 
nodal yield per neck side and also the harvested nodal count broken down into neck 
levels, with special regards to level Ib and IIa, being the regions of possible fistula 
formation. 
 
Table 5: Patient characteristics to comparison the timing of neck dissection vs. TORS 
Variable Control group Experimental group 
        No. of patients (%) No. of patients (%) 
Cohort 21 20 
 
Sex 
  
 
male 16 (76.2) 15 (75.0) 
 
female 5 (23.8) 5 (25.0) 
Age, years (median 63.9, range 52-81) (median 66.9, range 47-83) 
 
<65 11 (52.4) 8 (40.0) 
 
≥65 10 (47.6) 12 (60.0) 
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Tumor site 
 
Oropharynx 19 (90.5) 14 (70.0) 
  
Base of tongue 6 (28.6) 5 (25.0) 
  
Tonsillo-lingual 
angle 4 (19.0) 2 (10.0) 
  
Tonsil 8 (38.1) 5 (25.0) 
  
Soft palate 1 (4.8) 2 (10.0) 
 
Hypopharynx 2 (9.5) 6 (30.0) 
  
Piriform fossa 2 (9.5) 6 (30.0) 
pT classification 
  
 
T1 9 (42.9) 7 (35.0) 
 
T2 12 (57.1) 9 (45.0) 
 
T3 0 4 (20.0) 
pN classification 
  
 
N0 9 (42.9) 5 (25.0) 
 
N1 5 (23.8) 7 (35.0) 
 
N2a 1 (4.8) 0 
 
N2b 4 (19.0) 6 (30.0) 
 
N2c 0 2 (10.0) 
 
N3 2 (9.5) 0 
TNM Stage 
  
 
I-II 8 (38.1) 4 (20.0) 
 
III-IV 13 (61.9) 16 (80.0) 
 
 
3.5.9.1. TORS Procedures 
 
After obtaining informed consent, all patients underwent transoral robotic-assisted 
resection for their oropharyngeal or hypopharyngeal primary tumour using the da Vinci 
Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA, USA), as described 
previously by Lörincz et al. [6, 25]. The lateral superior or medial pharyngeal 
constrictor muscles were partially resected with the tumour en bloc, when oncologically 
required. The clear margin status of each TORS-resection was confirmed by means of 
intraoperative frozen section histology; in cases with close or involved margins, an 
immediate re-resection was performed subsequently, during the same robotic session. A 
soft silicone nasogastric feeding tube was placed at the end of each TORS-procedure, 
still in general anaesthesia. 
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3.5.9.2. Neck Dissections 
 
Appropriate neck dissections were performed according to the clinical and radiological 
staging of the neck. Even in the cN0-cases, at least an elective, ipsilateral selective neck 
dissection in levels II-IV was performed. If clinically suspect or positive nodes were 
detected in extra levels or contralaterally, additional levels or bilateral necks were 
dissected, respectively. Resection of the submandibular gland was included according to 
the surgeon‟s preference upon the presence of clinically suspect lymph nodes in level 
Ib. Neck dissections were performed either concurrently with the TORS-procedure 
(control group) or in a staged manner (experimental group). 
 
In the control group, 9 (42.9%) patients received an ipsilateral neck dissection 
immediately after their primary tumour resection, during the same general anaesthesia 
session. Twelve (57.1%) patients were concurrently neck dissected bilaterally (Table 6). 
Patients in the experimental group underwent 10 (50%) ipsilateral neck dissections and 
10 (50%) bilateral neck dissections as staged procedures, with the primary tumour 
resection (first procedure) and the neck dissection (second procedure) in two separate 
general anaesthesia sessions (Table 6). The median time interval between the two 
procedures was 8.40 days with a range from 3 to 28 days. 
 
Preoperatively, following physical examination of the neck and a panendoscopy in 
general anaesthesia, all cervical lymph node levels were examined by means of MRI- 
and/or CT-scan with contrast, with regards to clinical and radiological evidence of 
lymph node metastases. In the control group, 14 patients (66.7%) were staged as cN-
positive, versus 15 similarly classified patients (75%) in the experimental 
group.Concerning the levels included in the ipsilateral neck dissections, all patients in 
both groups underwent a regional lymphadenectomy at least in levels II, III and IV. In 
addition to these levels, level I was also included in the ipsilateral neck dissection in 18 
cases (85.7%) of the control group, whereof 4 patients (19%) also underwent a 
submandibulectomy as part of the level Ib clearance. In the experimental group, 10 
(50%) patients received an ipsilateral level I dissection, with 1 (5%) patient including a 
submandibulectomy. 
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Table 6: Patient characteristics to compare the timing of neck dissection vs. TORS 
Variable   Control group Experimental group 
      No. of patients (%) No. of patients (%) 
 
Cohort 
 
21 20 
 
Total ND performed 33 30 
 
unilateral 9 (42.9) 10 (50.0) 
 
bilateral 12 (57.1) 10 (50.0) 
Days between TORS and ND (median 0, range 0) (median 8.4, range 3-28) 
 
Ipsilateral ND 
  
 
Level I 18 (85.7) 10 (50.0) 
  
incl. submandibular gland 4 (19.0) 1 (5.0) 
 
Level II 21 (100.0) 20 (100.0) 
 
Level III 21 (100.0) 20 (100.0) 
 
Level IV 21 (100.0) 20 (100.0) 
 
all other levels 5 (23.8) 3 (15.0) 
 
cN+ 14 (66.7) 15 (75.0) 
 
pN+ 12 (57.1) 15 (75.0) 
 
pN+ in Level I 0 1 (5.0) 
 
pN+ in Level II 12 (57.1) 11 (55.0) 
 
Abbreviations: 
ND = neck dissection, 
TORS = transoral robotic surgery 
 
   
3.6. Defining the Standard TORS-Algorithm 
 
Our standardized approach to include TORS, and to optimize its role in the 
multidisciplinary management of head and neck cancer patients, are based on the 
following institutional experience and data: 
 
To date, more than a hundred head and neck cancer patients have been treated using 
TORS as the primary modality at our department. Of them, the functional and early 
oncologic outcomes of our first 35 oropharyngeal TORS-patients with one year follow-
up have been previously published [6]. Since then, even the 2-year survival outcomes of 
our first 50 TORS-patients with HNSCC have become available. 
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The latter, to date unpublished data show their disease specific survival rate at 96%, 
while the overall survival was 94%. The two-year disease free survival rate was 88%, 
and the two-year recurrence-free survival was 80%. Of the 10 patients with recurrent 
disease, local recurrence, nodal recurrence and distant metastasis occurred in five, three, 
and in two cases, respectively. This results in a local recurrence rate of 10% after 2 
years. 
 
From our first 50 consecutive HNSCC TORS-cases, including 43 oropharyngeal, 4 
hypopharyngeal, 2 combined hypopharyngeal/supraglottic and 1 supraglottic SCC, 
twenty-four patients had T1, twenty-three T2, two T3 and one had a T4a primary 
tumour. There were 18 patients with overall Stage I-II and 32 patients with Stage III-IV 
disease. 
 
Following transoral robotic resection of their primaries and appropriate neck 
dissection(s) as indicated, adjuvant treatment could be spared in 20 patients (40%). 
Another 5 patients refused the recommended adjuvant therapy (two of them later  
developed recurrent nodal disease, both were successfully salvaged with 
chemoradiotherapy). Seventeen patients received 60 Gy adjuvant radiotherapy and 8 
patients underwent 66 Gy adjuvant chemo-radiotherapy. 
 
In 37 patients (74%) altogether, adjuvant treatment could be either completely spared, 
or the chemotherapy component could be omitted and the radiotherapy could be 
reduced by at least 10 Gy, compared to the standard primary chemoradiation protocol 
with 70 Gy. Adding the 3 patients who refused adjuvant treatment and did not develop a 
recurrence to date, this figure goes up to 80%. 
 
3.6.1. Constructing the TORS-Management Framework 
 
In constructing a framework for the use of TORS in the multidisciplinary management 
of pharyngeal and laryngeal malignancies, one must first define the principal 
management question: What first-line treatment modality is most likely to minimize 
morbidity and maximize post-treatment function while maintaining oncologic safety? 
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[3] In considering TORS as the answer, one must be aware that the current surgical 
access afforded by TORS limits its use primarily to T1-T2 tumors. Some TORS 
surgeons also advocate for the inclusion of selected T3 tumors as an off-label use of the 
daVinci Surgical System. Next, one must consider the contemporary geographical first-
line modality that TORS would be superseding; in the U.S. it is primarily CRT, whereas 
in Europe it is TOLM or CRT. As such, the specific advantages and limitations of 
TORS with respect to the established first-line modality within a given HNSCC center 
must be clearly defined and communicated to the patient and multidisciplinary 
treatment team. Third, it is imperative that the treatment team have a clear construct of 
the current significance of HPV positivity in tumor response to treatment and the impact 
– or rather, the lack of impact – this should have on the decision to pursue TORS as a 
first-line modality. Finally, in any discussion of HNSCC, consideration must always be 
given to proper management of the regional nodal basin in the neck. 
 
3.6.1.1. Access 
 
For TORS to be considered in the treatment algorithm of HNSCC, appropriate access to 
the tumor must be feasible. Appropriate access is that which is likely to allow for en-
bloc resection of the primary with preferably at least 5 mm margins in all planes. In 
considering TORS over other modalities, the resection must be realistically achievable 
without the likelihood of significant long-term functional impairment.  Appropriate 
access requires a) the ability to visualize the entire tumor with the daVInci Surgical 
System endoscope b) the ability to circumferentially access and resect the tumor with 
the appropriate robotic instruments c) the ability to visualize nearby critical structures 
and maintain hemostasis. 
 
Prior to multidisciplinary tumor board discussion, the TORS surgeon must be able to 
reliably assess the feasibility of achieving appropriate access based on physical 
examination, endoscopy, and imaging. It is critically important to consider patient 
factors such as mouth opening, dentition, neck length, and jaw size in addition to tumor 
size and position. At our institution, pre-treatment examination under anaesthesia 
(EUA) and panendoscopy is done for all potential TORS candidates using the same 
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mouth gag (retractor system) that will be used during the ensuing robotic procedure, to 
fit the individual patient‟s anatomy and tumor and to ensure adequate access will be 
possible. 
 
3.6.1.2. Advantages of First-Line TORS over Conventional Modalities 
 
In the U.S., the decision to pursue TORS as first-line therapy for T1-T2 oropharyngeal 
and laryngeal cancers must be made with regards to the expected functional and long-
term morbidity advantages TORS provides over conventional CRT. In Europe, the 
decision to use TORS must be made with respect to CRT from a functional perspective, 
and with regards to TOLM from technical, economic, and oncologic safety 
perspectives. As a result, for TORS to be successfully implemented on both sides of the 
Atlantic, its use must result in less morbidity and better functionality than primary CRT, 
while providing the surgeon with an economically feasible tool that expands the scope 
of tumors that may be resected through a minimally invasive trans-oral approach 
considerably further than what is possible using TOLM. 
 
3.6.1.2.1. Advantages of Minimally Invasive Transoral Surgery 
over Primary Chemo-Radiation Therapy 
 
First-line CRT with curative intent for HNSCC typically consists of fractionated RT 
delivered concurrently with chemotherapeutic agents. The most common protocol 
involves a total dose of 70 Gy delivered using 35 fractions over 7 weeks to the gross 
tumor volume (GTV), which includes the primary tumor and grossly involved nodes, 
and a dose of 56 - 60 Gy to the clinically negative nodal basin, known as the clinical 
treatment volume (CTV). Concurrent weekly delivery with single agent cisplatin or 
carboplatin is typical, with some favoring the addition of 5-fluorouracil in combination. 
Single-agent cetuximab is advocated for use in patients with contraindications to the 
highly toxic platinum agents. 
 
Proponents of first-line CRT often cite the „organ-sparing‟ success rates shown in the 
RTOG 91-11 for laryngeal malignancies.[76] Such „organ-sparing‟ advantages over 
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first-line surgery are increasingly being called into question. Numerous studies have 
reported long-term PEG-dependency rates on the order of 30-50% following primary 
CRT for pharyngeal and laryngeal malignancies.[77] This is principally the result of 
CRT induced fibrotic changes in the base of tongue and pharyngeal musculature leading 
to severely compromised swallowing function and subsequent aspiration. Other long-
term complications of high dose RT to the head and neck – that only tend to worsen 
over time – include loss of laryngeal sensation, accelerated tooth decay, xerostomia, 
accelerated carotid stenosis, osteoradionecrosis of the mandible (especially over 60Gy 
to the tonsillar region), radiation induced sarcomas, and carotid blowouts. These severe 
complications are routinely seen by head and neck surgeons. It is clear that „organ-
sparing‟ and „function-preserving‟ are not synonymous; all those involved in the 
treatment decision process – most importantly the patient – must understand this critical 
point. Additionally, one must also consider the long-term deleterious systemic effects 
and impact on overall survival associated with the use of highly cytotoxic 
chemotherapeutic agents in primary CRT. 
 
Trans-oral surgical approaches to T1 and T2 pharyngeal and laryngeal tumors 
principally involve tumor excision without defect reconstruction. Such ablative 
procedures and the resultant post-operative scarring may also result in significantly 
compromised speech and swallowing function, the latter resulting in PEG dependency. 
However, such an outcome is exceedingly rare following trans-oral excisions of T1 and 
most T2 malignancies.[22, 78-80] Larger T2 carcinomas represent a group where the 
likely oncologic and functional outcomes of a given first-line management plan – be it 
CRT, open surgery with or without free-flap reconstruction, or trans-oral approaches – 
must be carefully considered. Although controversial, most experts would currently 
agree that open surgery with free flap reconstruction for T3 and T4 carcinomas of the 
upper aerodigestive tract is unlikely to deliver significantly superior functional results in 
terms of deglutition and articulation over primary CRT. 
 
The ideal first-line surgical candidate is one with disease that is completely amenable to 
resection without the need for adjuvant therapy. Reducing the number of treatment 
modalities is an important part of reducing overall patient morbidity [3]. However, 
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whenever surgery is considered in place of primary CRT, the possibility of the need for 
adjuvant therapy always exists. In order to justify its first-line use, TORS must be shown 
to either reduce the need for adjuvant therapy altogether, or result in such a low level 
of morbidity that the additional morbidity of any required adjuvant therapy remains 
considerably lower than that of primary CRT alone. 
 
When single-modality surgical treatment is possible, typically consisting of an open 
neck dissection and TORS resection of the primary, justification of surgery in place of 
CRT for T1-T2 tumors is relatively straightforward, especially in younger patients with 
long life expectancies. In cases where adjuvant therapy is likely be required, such as 
with clinically node positive (cN+) disease, the advantage of first-line TORS over 
primary CRT decreases but it is not necessarily eliminated. Assuming adequate surgical 
margins are achieved and no adverse factors are noted on final pathology, adjuvant RT 
to the primary site may be completely avoided reducing local complications. Adjuvant 
RT to the neck may be avoided for N0 or N1 disease without nodal extra-capsular 
extension (ECE), and the dose may be reduced by 10 Gy or more following complete 
resection of N2 or higher disease compared to primary CRT. Adjuvant chemotherapy 
may be avoided altogether in the absence of ECE following definitive surgical excision. 
For many patients, the avoidance of chemotherapy alone warrants the use of surgery as 
a first-line therapy, regardless of whether adjuvant post-operative RT is required. 
 
3.6.1.2.2. Advantages of TORS over TOLM and Open Surgery 
 
In centers where trans-oral resections of early pharyngeal and laryngeal tumors have 
been routine practice by means of TOLM, adoption of TORS must provide advantages 
that justify its increased costs, specifically in Europe. Here, although the daVinci 
Surgical System has typically been purchased for other specialties of the same hospital, 
the use of the EndoWrist instruments, the daVinci-specific drapes, and a fair, time-
proportional share of the service and maintenance costs of the robot add up to an extra 
cost of approximately 1200-1500 Euros per TORS-case. In our inter-departmental 
billing system, this amount would be billed to the Dept. of ENT. The way we are able to 
balance these extra, TORS-related costs is that post-TORS patients require less or no 
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postoperative intensive care (ICU) or intermediate care (IMC) as well as an overall 
shorter hospital stay compared to those treated with open surgery. In the above 
mentioned inter-departmental billing system, one night in the ICU costs approximately 
800 Euros, billed to the referring department within the hospital. Consequently, if we 
are able to spare just one ICU night by using TORS in place of open surgery, it 
compensates already more than the half of the extra, TORS-specific costs. In addition to 
this, as with all trans-oral approaches, use of TORS avoids the significant surgical 
access-related morbidity associated with open procedures. Post-operative delay in return 
to oral intake and ambulation is significantly shortened. Common post-operative 
complications such as pharyngocutaneous fistulas, infections, and those associated with 
long-term hospital admissions and major surgeries (deep-vein thrombosis, pulmonary 
embolism, and pulmonary edema, for example) are significantly reduced. 
 
However, TORS is simply another approach to trans-oral surgery; the daVinci System 
must be viewed as a surgical tool with its own limitations, and dependent on its 
operator. The robot will not make one a better surgeon. With this in mind, using the 
daVInci Surgical System does have significant advantages over TOLM. The TORS 
learning curve is considerably less steep than that for TOLM [16]. The high-definition, 
deep depth of field, 3D-view afforded by the robotic endoscope allows for significantly 
improved tumor visualization. The endo-wristed maneuverability, high degree of 
freedom and movement scaling afforded by the robotic instruments allows for 
significantly improved dexterity over TOLM. The line-of-sight, tangential-only cutting, 
and piece-meal tumor resection limitations of TOLM are eliminated with TORS. This 
results in a significant increase in the scope of tumors that may be resected trans-orally 
in an oncologically sound en-bloc fashion (such as large T2 tumors), far beyond that 
which would be achievable using TOLM. 
 
3.6.1.3. The HPV-Epidemic and TORS 
 
Until community immunity is achieved through vaccination, the incidence of HPV 
associated HNSCC and the ensuing implications on management will continue to rise. 
In most advanced centers, biopsies of HNSCC are now routinely tested for evidence of 
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HPV infection. The two most common tests to detect HPV are p16 protein detection via 
immunohistochemistry staining and HPV-DNA detection and typing via in-situ 
hybridization or via a polymerase chain reaction. Not to be confused with the oncogenic 
HPV-16 viral subtype, the p16 protein is a kinase encoded by the host epithelial cell that 
acts to block progression from G1 to S phase of the cell cycle.  In oncogenic HPV 
infected cells (HPV16 and HPV18, primarily), p16 protein production is up-regulated 
due to blockade of p53, p21, and Rb function by the E6 and E7 viral oncogene 
products.[81] This up-regulation is detected against a p16 antigen, with a sensitivity of 
97% and specificity of 84% for detection of E6/E7 protein producing HPV 
infection.[82] At our institution, patients must also demonstrate HPV-DNA positivity to 
be classified as having HPV-positive tumors. 
 
Since the HPV HNSCC epidemic was first noted, considerable focus has been placed on 
the differential response of HPV-associated OPC to radiation therapy (RT). It has been 
well documented that HPV-driven tumors are more radiosensitive than those driven by 
DNA damage caused by traditional risk factors such as alcohol and tobacco, in large 
part due to differences in residual p53 function.[83, 84]There is much debate as to 
whether radiation doses may be „de-escalated‟ for patients with tumors demonstrating 
oncogenic HPV infectivity. However, the simple presence of oncogenic HPV infectivity 
in a head and neck tumor does not exclude or lessen the possible contributions of other 
carcinogenic insults on disease progression. Until improved molecular diagnostics are 
available, HPV infectivity must not be viewed as a favorable feature in the patient with 
a positive history of prolonged exposure to alcohol and tobacco; HPV is not a „cure‟ for 
a tumor that resulted from a lifetime of smoking and drinking. For this reason, the term 
HPV-driven is defined for HPV-positive tumors in patients without classical risk factors 
for HNSCC. Such tumors must be differentiated from HPV-associated tumors, those 
arising in patients with classical risk factors for HNSCC who also demonstrate tumors 
testing positive for oncogenic HPV infection. 
 
For patients with HPV-driven tumors, significant improvement in disease specific and 
overall survival following first-line CRT for OPC has been consistently demonstrated in 
comparison to those with tumors driven by classical risk factors.[84-87] In many 
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centers, this evidence has led to the development of a dogma that most – if not all – 
patients with potentially curable HPV-driven OPC should be managed with first-line 
CRT. However, this dogma ignores increasing evidence that surgery for HPV-driven 
tumors offers equivalent, if not improved, survival benefits.[88] Currently there is no 
evidence to support the first-line use of CRT over surgery for patients with T1-T2 HPV-
driven tumors. The fact that HPV-driven tumors are more radiosensitive does not justify 
the non-consideration of surgery as first-line management. Not only does the younger 
age and improved general health of patients with HPV-driven tumors make them better 
surgical candidates, it provides a powerful argument against favoring the use of primary 
CRT, the morbidity of which tends to increase over time. 
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4. RESULTS 
 
4.1. Patients with OPSCC 
 
We evaluated the prospectively collected data of 35 OPSCC-patients who underwent 
TORS at our institution between September 2011 and April 2013 (19 months) as their 
primary treatment modality. For the detailed description of their tumor status, we refer 
to the “Patient selection OPSCC” paragraph 2.3.1. above (Table 2). There were 26 
males and 9 females, their mean age being 65 years (range 49-84 years). Twelve 
patients had a positive HPV-status, altogether 11 males and 1 female. Appropriate neck 
dissections, as warranted upon their cTNM-classification, were performed either in the 
same operation or as a staged procedure. Following each TORS-resection, all relevant 
margins were evaluated intraoperatively by frozen section histology, and a robotic re-
resection followed during the same session if close or involved margins with invasive 
cancer or high grade dysplasia (equivalent to carcinoma in situ) were reported by the 
pathologist. 
 
4.1.1. Preliminary Oncological Outcomes 
 
Completeness of resection (margin status): Clear resection margins were achieved 
altogether in 33 of the 35 cases (94.3%). In 19 cases, the closest margin was ≥5mm, 
which we classify as a well clear margin status. In 14 cases, the closest margin was 
≥2mm but <5mm, classified as clear, but close margins. Finally, in 2 cases, the closest 
margin was <2mm, which we consider as being potentially involved (Table 7.). The 
latter was reported on two occasions in the definitive histology, despite the negative 
frozen sections intraoperatively. These two cases were salvaged surgically within a 
week following the robotic procedure, with an open re-resection and free flap 
reconstruction. 
 
Need for adjuvant therapy: After having completed robotic resection followed by their 
final histopathological report, all patients were re-discussed at the Tumor Board for 
adjuvant therapy (Table 7.). 
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Table 7:Early oncologic outcomes of TORS for OPSCC[6] 
 
 
Adjuvant treatment was completely spared in 13 cases (37.1% of all patients)[59], based 
on their favorable pTNM-classification and completeness of resection, including neck 
dissections with a sufficient nodal yield. With one exception, they have all been free of 
recurrent disease to date. One of them (1/13) presented with a local recurrence 12 
months after the robotic resection, which was initially performed with a closest 
resection margin of 5mm for a T1 N0 oropharyngeal cancer. This patient has ultimately 
undergone a Re-TORS procedure with repeatedly well clear margins (no dysplasia 
involved in the new margins). 
 
Fourteen patients received postoperative adjuvant radiotherapy, two of them (2/14) 
presented with recurrence after 4 and 9 months, with an initial closest resection margin 
of 5mm and 3mm, respectively; the former was salvaged with an open resection and 
free flap reconstruction for local recurrence, the latter ultimately deceased of distant 
metastatic disease. Both of them had a Stage IVA disease at the initial presentation. 
 
Five further patients received postoperative adjuvant chemo-radiotherapy, they have all 
been free of recurrence to date (0/5). 
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Finally, 3 patients refused any form of adjuvant treatment recommended by the Tumor 
Board, and 2 of them developed recurrent disease after 5 and 8 months (2/3), with an 
initial closest resection margin of 8mm and 5mm, respectively. Both of them had a 
Stage IVA disease at the initial presentation, and both of them were successfully 
salvaged with a full-dose chemo-radiotherapy. 
 
Recent follow-up status: At the time of the last follow-up visit (median: 13 months), 30 
patients (85,7%) had been recurrent-free (disease-free survival, Fig.1.), and altogether 
34 patients were alive as well as tumor-free in the same time (overall survival, Fig.2.). 
There had been a total of 5 patients (14.2%) with early recurrent disease, two of them 
having previously refused adjuvant treatment despite the recommendation of our 
multidisciplinary head and neck tumor board, but ultimately both of them successfully 
salvaged with full-dose chemoradiotherapy. One patient died of recurrent disease with 
distant metastasis (disease-specific survival, Fig.3.). Two patients were successfully 
treated with further surgery (one with Re-TORS and one with open surgery with free 
flap reconstruction, respectively) for their recurrent oropharyngeal cancer. Among the 
five patients who developed recurrent disease, only one of them had an initially HPV-
driven cancer. 
 
 
Fig.5: Disease-free survival in months [6] 
 
DOI:10.14753/SE.2015.1766
 46 
 
Fig.6: Overall survival in months [6] 
 
 
Fig.7: Disease-specific survival in months [6] 
 
Correlation of early recurrence with the initial pTNM-classification, adjuvant therapy, 
completeness of resection and HPV-status: Out of the five patients who presented with 
recurrent disease at their last follow-up appointment, four had initially Stage IVA 
disease (T1 N2a, with the closest resection margin being 8mm, refused adjuvant 
therapy, HPV-driven;  T1 N2b, closest margin 3mm, refused adjuvant therapy; T2 N2b, 
closest margin 5mm, received adjuvant radiotherapy of 60Gy; T2 N2c, closest margin 
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3mm, received adjuvant radiotherapy of 60Gy, respectively). Among the patients who 
developed recurrence, one had initially Stage I disease (T1 N0, closest margin 5mm) 
and no adjuvant therapy was offered to this patient (Table 8.). The patient with initially 
T1 N2a disease was the only one with a positive HPV-status among the 5 patients with 
recurrence. 
 
Table 8: Subset analysis of recurrences after TORS for OPSCC (5 of 35 patients)[6] 
 
 
4.1.2. Functional Outcomes 
 
The outcome measures we used to assess our functional results (Table 9.) were  
swallowing function represented by the duration of nasogastric tube feeding and/or 
percutaneous endoscopic gastrostomy (PEG)-feeding, rate of postoperative bleeding, 
number of elective and emergency tracheotomies, days of intensive care, number of 
days intubated and days of intermediate care [89]. 
 
Swallowing function: None of the patients had a gastrostomy tube at the last follow-up 
visit, they have all been recently on full oral diet with an acceptable/reasonable to 
normal physiological swallowing. A nasogastric tube was placed through the non-
operated side of the pharynx following the robotic resection still in general anaesthesia, 
by default in all TORS-patients. The median duration of postoperative nasogastric tube 
DOI:10.14753/SE.2015.1766
 48 
feeding was 5 days (range: 1 day to 25 days). There were 16 patients who received a 
PEG-tube: this subgroup consisted of all five patients who received postoperative 
adjuvant chemoradiation and eleven patients with postoperative adjuvant radiotherapy, 
with a median duration of 29 days PEG-feeding (range: 7 to 150 days). None of the 
patients treated with surgery alone needed PEG-feeding. 
 
Elective, temporary tracheotomy was performed at the discretion of the surgeon based 
on the estimated risk of postoperative upper airway obstruction due to mucosal swelling 
and the risk of postoperative bleeding, in a total number of 3 patients. The elective  
tracheotomy was closed within one to two weeks post-TORS, simultaneously with the 
staged neck dissection(s), if applicable. 
 
Table 9: Functional outcomes of TORS for OPSCC[6] 
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Days intubated, intensive and intermediate care: By default, all TORS patients were 
kept intubated and have spent the first postoperative night at the intensive care unit 
(ICU). Extubation followed on the first post-TORS day in the presence of the surgeon, 
after having observed the resection site and the entire laryngo-pharyngeal mucosa as 
well as performed a positive leak-test. The median number of days spent in the ICU was 
1 day (range: 1 to 5 days), the median number of days intubated was 1 day as well 
(range: 1 to 2 days). The median number of days spent it the intermediate care (IMC) 
was also 1 (range: 1 to 3 days). 
 
Postoperative bleeding rate: On two occasions, patients had to be taken back to theatre 
due to postoperative bleeding from the resection site, on day 1 and on day 6, 
respectively. These bleedings were stopped using bipolar diathermy and liga-clips. 
 
Emergency tracheotomy was performed to the patient who presented with postoperative 
bleeding on day 1, and for another patient due to upper airway obstruction on the basis 
of delayed swelling of the pharyngeal mucosa on day 6. These tracheotomies were also 
closed within one to two weeks. 
 
4.2. Patients with HPSCC 
 
The median age of the patients was 64 years. There were four males and one female 
patient. There were two p16-positive tumours, only one of those being HPV-DNA 
positive in the same time. The patient presented with the latter tumour was a life-long 
non-smoker and non-drinker, supporting the theory that HPV can play a role outside of 
the oropharynx as well. Preoperatively, three tumours were classified as cT1 and two as 
cT2, and one of the cT1 tumours was pathologically upstaged to pT2 postoperatively. 
Following their TORS-procedure, they all underwent an ipsilateral selective neck 
dissection including levels IIa, IIb, III and IV in a concurrent fashion; total nodal yield 
was over 20 in each case. Despite recent recommendations regarding Level IIb in a cN0 
neck, we did harvest the entire Level II in these patients in order to maximize nodal 
yield and stay oncologically as safe as possible even without adjuvant treatment. 
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4.2.1. Preliminary Oncological Outcomes 
 
Completeness of resection (margin status): Clear resection margins were achieved in all 
cases. In four patients, the closest margin was ≥5mm, which we classify as a well clear 
margin status [18]. In one single case, the closest margin was 4mm (Table 4). 
 
Need for adjuvant therapy: After having undergone robotic resection followed by their 
final histopathological staging, all patients were re-discussed at the Tumour Board for 
adjuvant therapy. Adjuvant treatment was completely spared in 3 cases, based on their 
favourable pTNM-classification and completeness of resection, including neck 
dissections with a sufficient nodal yield. One patient received adjuvant radiation alone 
(60 Gy) for his pT2 pN0 hypopharyngeal cancer, based on adverse features shown in his 
final histology such as poor differentiation, as well as perineural and lymphovascular 
invasion. One patient received 66Gy adjuvant chemoradiotherapy for his pT2 pN2b 
disease, which may question the necessity of the surgery [90], being almost as much as 
a primary chemoradiation of 70Gy. In his case, we indicated the surgery hoping to spare 
him 10Gy of radiation and the chemotherapy component of the adjuvant treatment, 
without radiologically suspected nodal extracapsular spread (ECS) in the neck. The 
latter feature was nevertheless evident in the final histology, so an adjuvant 
chemotherapy had to be included with the radiation increased up to 66Gy (Table 10). 
 
Recent follow-up status: At the time of their last follow-up visit (median: 18 months), 
all patients had been recurrent-free and altogether four patients were alive as well as 
tumor-free in the same time. One patient died of other disease (heart attack). Their early 
oncologic outcomes with their last follow-up status are summarized in Table 10. 
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Table 10.: Oncologic and functional results following TORS for HPSCC[25] 
 
Cont’d. Table 10.: Oncologic and functional results following TORS for HPSCC[25] 
 
Abbreviations: 
CRT: chemoradiotherapy 
RT: radiotherapy 
FEES: Functional Endoscopic Evaluation of Swallowing 
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4.2.2. Functional Outcomes 
 
No conversion to open surgery was necessary. Blood loss was minimal in all cases [62]. 
Mean robotic setup time was 31 minutes (range: 16-48 minutes). Because of the rather 
horizontal retractor angle required for the hypopharyngeal access, edentulous patients 
were considerably easier to set up. Once the retractor was in position, docking of the 
robotic arms took an additional 18 minutes (mean; range: 8-22 minutes). The robotic-
assisted resection itself, i.e. the mean console time was 44 minutes (range: 27-59 
minutes) [16]. All patients underwent an ipsilateral selective neck dissection (levels II-
IV) in a concurrent fashion. The outcome measures we used to assess our functional 
results were swallowing quality represented by the duration of nasogastric tube feeding 
and/or PEG-feeding, rate of postoperative bleeding, number of elective and emergency 
tracheotomies, days of intensive care, number of days intubated and days of 
intermediate care [91] (Table 4). 
 
Swallowing function: Median duration of nasogastric tube feeding was 5.5 days (range: 
3-18 days). One of the patients (patient Nr.4.) with a recurrent hypopharyngeal tumor 
after primary chemoradiation, had a PEG-tube prior to surgery, as she developed severe 
dysphagia during and after her conservative treatment which made her long-term PEG-
dependent. In her case, TORS was used for salvage surgery [92]. Another patient 
(patient Nr.2.)  received a PEG-tube on the 18. postoperative day, because he needed 
adjuvant chemoradiation and his already impaired swallowing function was expected to 
deteriorate further during his adjuvant treatment. All other patients resumed full oral 
diet within the first postoperative week with a reasonable to normal physiological 
swallowing [93]. Functional endoscopic evaluation of swallowing (FEES) was carried 
out at 1 week, 3 months and 6 months postoperatively (Table 10.).  
 
Elective, temporary tracheotomy was performed in one case (patient Nr.3.) due to 
postoperative mucosal swelling and difficult intubation in the anamnesis. The 
tracheotomy was closed on the 6. postoperative day. However, possible arguments for a 
routinely performed elective tracheotomy in hypopharyngeal and supraglottic TORS-
cases are detailed in the Discussion. 
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Days intubated, intensive and intermediate care: By default, initially all our TORS 
patients were kept intubated for 24 hours and have spent the first postoperative night at 
the ICU. Extubation followed on the first post-TORS day in the presence of the 
surgeon, after having observed the resection site and the entire laryngo-pharyngeal 
mucosa as well as performed a positive leak-test. 
 
Postoperative bleeding rate: In this subgroup of patients, there was neither any 
postoperative bleeding nor need of an emergency tracheotomy. 
 
4.3. Neck Dissection Outcomes 
 
Harvested lymph node counts from Group 1 and Group 2 were compared in two 
categories: 1.) Nodal count comparison per neck level, and 2.) Overall nodal yield from 
the entire neck. 
 
4.3.1. Statistical analysis 
 
4.3.1.1. Harvested lymph node count comparison per neck level 
 
The mean harvested lymph node count per level, irrespective of which level it is, was 
5.89 with a 95% CI ranging from 5.33 to 6.44 in Group 1, and 3.90 with a 95% CI 
ranging from 3.47 to 4.33 in Group 2, representing a mean difference of 1.99 lymph 
nodes per level (p<0.001). 
 
The comparison of mean harvested lymph node counts broken down into each 
individual neck level (Fig.8.) gave the following results: 
 
Level I: 3.38 with a 95% CI ranging from 2.74 to 4.01 in Group 1, and 1.67 with a 95% 
CI ranging from 0.99 to 2.35 in Group 2, representing a mean difference of 1.75 lymph 
nodes (p<0.001). 
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Level II: 6.80 with a 95% CI ranging from 5.89 to 7.71 in Group 1, and 4.61 with a 
95% CI ranging from 3.87 to 5.36 in Group 2, representing a mean difference of 2.23 
lymph nodes (p<0.001). 
 
Level III: 6.06 with a 95% CI ranging from 5.23 to 6.89 in Group 1, and 3.77 with a 
95% CI ranging from 3.14 to 4.40 in Group 2, representing a mean difference of 2.33 
lymph nodes (p<0.001). 
 
Level IV: 6.17 with a 95% CI ranging from 5.30 to 7.03 in Group 1, and 3.74 with a 
95% CI ranging from 3.11 to 4.38 in Group 2, representing a mean difference of 2.43 
lymph nodes (p<0.001). 
 
Level V: 5.34 with a 95% CI ranging from 4.01 to 6.67 in Group 1, and 5.49 with a 95% 
CI ranging from 4.32 to 6.66 in Group 2, representing a mean difference of -0.13 lymph 
nodes (p=0.868, not significant) 
 
The nodal yield advantage of Group 1 patients was highly significant in Levels I, II, III 
and IV, while the differences in Level V were not significant. 
 
4.3.1.2. Overall nodal yield 
 
In Group 1, the mean overall nodal yield from one side of neck was 22.53, with a 95% 
CI ranging from 20.43 to 24.63. In Group 2, the mean overall nodal yield from one side 
of neck was 15.00, with a 95% CI ranging from 13.37 to 16.63 (Fig.9.). The mean 
difference of 7.53 lymph nodes between the two groups is significant (p<0.001). 
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Fig.8: Nodal yield per neck level 
 
 
Fig.9: Nodal yield per neck side 
DOI:10.14753/SE.2015.1766
 56 
4.3.2. Timing of Neck Dissection in Patients Undergoing TORS 
 
4.3.2.1. Pattern of Spread 
 
Histopathological examination of the neck dissection specimens revealed pN-positive 
status in 12 (57.1%) patients of the control group, versus 15 (75%) patients of the 
experimental group. None of the patients in the control group showed histologically 
confirmed lymph node metastasis in level I, whereas one (5%) patient had a single 
positive lymph node in level I in the experimental group (Table 6). 
In 12 (57.1%) patients, the ipsilateral level II was determined as the primary lymphatic 
region of metastastic spread in the control group, versus 11 (55%) patients with a 
similar pattern of spread in the experimental group (Table 6). 
 
4.3.2.2. Nodal Yield 
 
Nodal yield is defined as the overall number of harvested lymph nodes in a regional 
lymphadenectomy. In the control group, 574 lymph nodes were harvested from 86 
dissected levels in the ipsilateral neck dissections, resulting in a nodal count of 6.7 per 
level. The nodal yield per neck side was 27.3 in the control group. In the experimental 
group, altogether 577 lymph nodes were harvested from 73 dissected levels in the 
ipsilateral neck dissections, resulting in a nodal count of 7.9 per level. The overall nodal 
yield per neck side was 28.9 in the experimental group. The difference between the 
overall nodal yield values of the two groups was not significant (Table 11). 
The nodal yield values broken down into each individual neck level are also listed in 
Table 11. Differences between the control group and the experimental group were not 
significant in levels I, II and III. The only significant difference in terms of nodal count 
between the two groups was observed in level IV, where more lymph nodes were 
harvested from patients in the experimental group than from those in the control group. 
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Table 11.: Comparison of nodal yield vs. the timing of neck dissections 
 
 
4.3.2.3. Intraoperative Complications 
 
During the concurrent and staged ipsilateral neck dissections, levels Ib and IIa were 
assessed for through-and-through communication, or pharyngocervical fistula 
formation. In the control group, two (9.5%) fistulae could be located versus one (5%) 
fistula in the experimental group (Table 12). 
All defects were primarily closed at the end of the procedure by placing myo-mucosal 
sutures into the pharyngeal constrictor muscles as well as by reconstruction using a 
pedicled local muscle flap of the digastric, omohyoid or sternocleidomastoid muscles, 
whichever was more convenient for the given defect in the given patient. Fibrin glue 
was not used in any of the cases. 
Patients received i.v. antibiotic coverage for 7 days with cefuroxim or clindamycin for 
having undergone clean-contaminated surgery due to pharyngocervical communication. 
 
4.3.2.4. Postoperative Complications 
 
Following TORS, patients were kept intubated for one night at the intensive care unit to 
prevent the possible consequences of mucosal swelling and/or postoperative bleeding, 
except those cases managed with elective temporary tracheotomy, which was only 
performed in a few selected high-risk patients [6]. 
Postoperative pharyngocutaneous fistula did not occur in any of the patients, 
irrespective of the timing of their neck dissection (Table 12). In the control group, one 
patient (4.8%) had a postoperative bleeding from the ipsilateral neck dissection site, and 
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two (9.5%) patients had postoperative bleeding from the primary TORS-resection site. 
Hemostasis has been achieved under general anaesthesia in each of those cases. 
In the experimental group, no bleeding occurred either from the neck or from the 
primary resection site. Other postoperative complications, such as hematoma, seroma 
and infection were documented and are listed in Table 12. The differences between the 
two groups were not significant in any regard. 
 
Table 12.: Comparison of complication rates vs. the timing of neck dissections 
 
 
4.4. Our Concept for TORS 
 
As a result of all the above considerations, we attempted to outline the points to follow 
when recommending TORS as the primary treatment for head and neck cancer patients, 
as shown in Table 13: 
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Table 13.: Step-by-step evaluation of potential TORS-candidates 
 
 
These considerations have also resulted in creating the following decision framework 
for head and neck cancer primary treatment at our institution, as shown in Table 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.1. Selecting the ideal TORS candidate: 
 
1. The patient has no general contraindications to surgery 
2. The primary tumor is functionally well resectable, without significant long-
term impairment 
3. There is no radiological sign of ECE 
4. Clear surgical margins (≥ 2 mm) are likely to be achieved for the primary 
tumor, ideally well clear (≥ 5 mm) margins are to be expected 
5. Surgery is likely to result in the reduction or elimination of adjuvant CRT 
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Table 14.: Decision algorithm for primary treatment of HNSCC patients 
 
Abbreviations: 
ECE: extra capsular extension 
TORS: trans oral robotic surgery 
SND: selective neck dissection 
mRND: modified radical neck dissection 
RND: radical neck dissection 
RT: radiotherapy 
CRT: chemo-radiotherapy 
ICT: induction chemotherapy 
Gy: Gray 
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5. DISCUSSION 
 
5.1.  Oropharyngeal SCC 
 
Transoral robotic surgery has several advantages over conventional endoscopic surgery 
of the upper aerodigestive tract, including trans oral laser microsurgery (TOLM). The 
latter provides with a tangential-only cutting plane due to the known line-of-sight issue, 
while a constant repositioning of the laryngoscope is often still necessary. As a 
consequence of these limitations, en bloc resection is not possible in many cases and a 
piece-meal technique is considered to be acceptable by a number of authors [90]. 
 
In contrast to TOLM, TORS has an ability to perform multi-planar en-bloc tumor 
resections under a magnified 3D-HD-view, which enables the assessment of the 
resection margins to be more accurate. The greater degree of freedom of the Endowrist-
instrumentation makes the margin safety of the resections equally sound to that of  
conventional  open surgery, but on a much lower cost of surgical morbidity. This, paired 
with a histopathologically most reliable margin assessment due to the en bloc resection, 
allows TORS to match the oncological safety of open surgery with the low morbidity of 
endoscopic laser surgery [90]. 
 
From a functional point of view, numerous clinical studies have shown improved post-
TORS swallowing function compared to other surgical modalities and to primary 
chemoradiation therapy, along with shorter hospital stay and faster recovery, as well as 
a more efficient return to work after completion of therapy [91]. However, the overall 
hospital stay may be longer than TORS alone would allow it to be, due to 
simultaneously performed neck dissection(s). If the neck dissection(s) are planned in a 
staged fashion, the patient has to undergo surgery and general anesthesia twice. Faster 
recovery means that adjuvant therapy, if indicated, may start sooner, which improves 
locoregional control. 
 
If TORS is going to succeed mid-term and long-term, its current indication field may 
need to be expanded, in order to allow select tumors with higher T-classification to be 
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treated transorally under well-defined conditions. One possibility would be a 
preoperative downstaging of the primary disease by administering induction 
chemotherapy prior to surgery. With a good response rate, this would allow to resect 
originally larger tumors with well clear margins and to obtain a reliable surgical staging 
of the neck by performing neck dissection(s) in a concurrent fashion. This combination 
may allow de-escalation of adjuvant treatment in patients who responded well to 
induction chemotherapy as well as had favourable histopathological parameters 
following TORS for their primary along with staging neck dissection(s) with a 
sufficient nodal yield [58]. 
 
Another possibility to selected treatment de-escalation would be to differentiate 
between the simply p16-positive cases and the truly HPV-driven cases. In our present 
study, HPV-status vs. HPV-drivennes are represented by the following figures: out of 
the 35 oropharyngeal squamous cell cancer (OPSCC) patients treated primarily (or even 
solely) with TORS, 18 showed p16-positivity with immunohistochemistry (51.4%). In 
many, especially overseas studies, they would have been automatically considered as 
being genuinely HPV-positive, which is not necessarily the case, as p16 is only a 
surrogate marker and can be positive for other reasons as well [94]. As we went further, 
HPV-DNA-testing showed positivity in only 12 cases of the eighteen p16-positive 
patients (34,3% of all 35 patients). In our definition, they have had the true HPV-
positive tumors (positive HPV-status). Whether their positive HPV-status was the main 
causative agent in developing their OPSCC, can be better estimated by looking at their 
smoking and drinking habits, as other possible causative factors. Taking the latter into 
consideration, only 9 patients fulfilled our criteria of having smoked less than 10 pack 
years and not consuming alcohol on a regular basis (25.7% of the 35 OPSCC-patients), 
and they are the ones having truly HPV-driven tumors in our opinion, not only a 
positive HPV-status[95]. 
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5.2. Hypopharyngeal SCC 
 
Specifically in the hypopharynx, transoral robotic surgery has several advantages over 
transoral laser microsurgery. The latter provides with a tangential-only cutting plane 
because of the known line-of-sight issue, while a constant repositioning of the 
laryngoscope is often necessary. As a consequence of these limitations, en bloc 
resection is not possible in many cases and a piece-meal technique is considered to be 
acceptable by a number of authors. To illustrate the access advantage of TORS over 
TOLM, Fig.10a and Fig.10b show the tumour of Patient Nr.1., being exposed first with 
a conventional Kleinsasser-B-laryngoscope, suitable for TOLM. The laryngoscope has 
to be repositioned to expose either the inferior, or the superior portion of the tumour, on 
Fig.10a and on Fig.10b, respectively. In contrast to this, the LARS retractor system, 
specifically designed for TORS, makes it possible to expose the entire tumor in a single 
position, shown on Fig.11. 
 
 
Fig.10a: Left piriform fossa / aryepiglottic fold tumour exposed with the Kleinsasser-B-
scope, showing only the inferior portion of the tumour [25] photo by BBL 
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Fig.10b: Left piriform fossa / aryepiglottic fold tumour exposed with the Kleinsasser-B-
scope, showing only the superior portion of the tumour [25] photo by BBL 
 
 
Fig.11: Left piriform fossa / aryepiglottic fold tumour exposed in its entirety with the 
LARS retractor system. No need for intraoperative repositioning [25] photo by BBL 
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As a consequence of this, TORS enables the surgeon to perform multi-planar en-bloc 
tumor resections under a magnified 3D-HD-view even in confined spaces like the 
hypopharynx, which allows a more accurate assessment of the resection margins. The 
greater degree of freedom of the Endowrist-instrumentation makes the margin safety of 
the resections equally sound to conventional open surgery, but on a much lower cost of 
surgical morbidity. This allows TORS to match the oncological safety of open surgery 
with the low morbidity of endoscopic laser surgery. 
 
Among our first fifty TORS-cases, consisting of predominantly oropharyngeal cancer 
patients but also including this subset of five hypopharygeal cases presented here, there 
were two postoperative bleedings that required intervention under re-intubation (4%), 
and neither of those occured from the hypopharynx. Although elective tracheotomy was 
not performed routinely in our series, the authors would like to emphasise that any 
bleeding in the hypopharynx or in the supraglottic larynx can be potentially life-
threatening by preventing re-intubation and blocking the airway. Therefore, performing 
an elective tracheotomy in hypopharyngeal and supraglottic TORS-cases may be 
reasonable in our opinion, especially if no neck dissection is done during the same 
session. 
 
In our series, all patients underwent an ipsilateral selective neck dissection in the same 
time, with subsequent ligatures of the ascending pharyngeal and lingual arteries, to 
reduce the risk of postoperative bleeding from the hypopharyngeal primary TORS-
resection site. However, in cases with a staged (delayed) neck dissection, we would 
recommend performing an elective tracheotomy even before starting the robotic 
resection, in order to remove the endotracheal tube from the surgical field for a better 
access as an extra benefit, in addition to securing the airway postoperatively. 
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5.3. Neck Dissection 
 
5.3.1. Explaining Level V 
 
There are two aspects to explain why the differences in Level V were not significant. 
First, in our patient cohort, there were a lot less neck dissections including Level V than 
including other levels, so there may be a low sample size issue when evaluating isolated 
results from Level V. Most selective neck dissections does not include Level V. Second, 
the fascia unwrapping technique affects primarily Levels II, III and IV in the N0 neck, 
as the plane of dissection starts to be developed along the leading edge of the 
sternomastoid muscle, so the nodal yield advantage might be concentrated to these 
lateral levels and may not be so much present in Level 5. 
 
5.3.2. General Considerations 
 
In the light of the current human papilloma virus (HPV) epidemic, application of 
intensity modulated radiotherapy (IMRT) and trans oral robotic surgery (TORS) [95], 
the emphasis is more on the quality of life today, and we have more data on the long-
term sequelae after 70-72 Gy primary chemoradiation than previously. It became also 
evident that the overall better prognosis of HPV-positive oropharyngeal squamous cell 
cancer (OPSCC) is applicable irrespective of the treatment modality [96], i.e. it applies 
to surgery as primary treatment as well [97-99]. In 2009, the Food and Drug 
Administration (FDA) approved TORS for T1 and T2 malignancies of the head and 
neck, opening the gate for a new paradigm shift taking currently place, moving back 
towards surgery in a minimally invasive, robotically assisted manner. In this scenario, 
aiming for an overall less toxic treatment package [94], the quality of the performed 
neck dissections is of paramount interest, both from a treatment-related morbidity and 
from an oncological aspect.  
 
In a therapeutic setting with a cN+ neck, it is still safe to perform functional and 
selective neck dissections with unwrapping the cervical fascia, as long as there is no 
macroscopic ECS. In an elective cN0 setting [100], improved nodal yield increases the 
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reliability of the information provided by the neck dissection specimen. This is of 
utmost importance when a decision on omitting adjuvant therapy relies on the pN0 
information based on an electively performed neck dissection. 
 
When balancing oncological safety with improved quality of life, it is especially 
important to identify those low-risk patients who may do just as well without any 
adjuvant treatment [101], e.g. the truly N0-patients. For these patients, the importance 
of a reliable surgical staging of the neck cannot be emphasized enough, as it serves as 
the basis of their management. 
 
Nodal yield and lymph node ratio are known to have a prognostic value in oral [40, 43] 
and in oropharyngeal [102] squamous cell carcinoma. The number of harvested lymph 
nodes did not differ significantly between the two groups in levels I, II and III. Level IV 
was the only level where a significant difference has been shown, although this level is 
not relevant with regards to the main question of this study, as intra- or postoperative 
pharyngocervical fistula formation is only expected in levels Ib and IIa after TORS. The 
latter outcome measures did not show a significant difference either. Despite the fact 
that most patients with a pN-positive neck status had their metastatic disease in level II, 
this circumstance did not increase the rate of fistula formation. In the same time, our 
low fistula rate did not compromise nodal yield. 
 
In the present context, besides concurrent or staged neck dissections, there is also a third 
option of performing the neck dissection prior to the TORS-procedure. This would 
merge some of the advantages of the two other options: it provides with a pre-TORS 
opportunity to ligate the relevant branches of the external carotid artery, should this be 
the preference of the surgeon; it would presumably decrease the risk of 
pharyngocervical fistula formation; and, it would allow for more convenient theatre list 
planning in certain hospitals and health systems. 
There are several reasons why we did not include this third option into our comparison. 
First, we only did it five times, because we generally prefer to remove the primary 
tumour at the earliest convenience to prevent (further) metastatic spread – ideally within 
two weeks after the initial diagnosis. 
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Second, even after a very thorough neck dissection with a high nodal yield, there are 
most likely always a few lymph nodes still left behind that may harbour new 
micrometastatic cells from the primary tumour until the TORS-procedure has been 
done. A neck dissection prior to the resection of the primary tumour may change the 
pattern of spread of the latter, and the physical manipulation during the delayed TORS-
procedure in the primary site may also release further tumour cells into the lymphatic 
system, that will no longer be treated if there is no indication for adjuvant treatment due 
to favourable tumour stage. 
Third, we always book the first available robotic theatre slot for our new cancer 
patients, as this is the rate-limiting step within our treatment algorithm, because booking 
the neck dissection is much less specific (in terms of surgeon, theatre, available scrub 
nurses etc.) and therefore much faster afterwards. 
 
5.4. TORS Concept 
 
If TORS is chosen as first-line treatment for HNSCC, oncological principles of en bloc 
resection and generous margins must be maintained, while preserving satisfactory 
function. Neither clear surgical margins nor organ function may be compromised on the 
account of preferring one over the other. Adjuvant CRT is not a solution for 
oncologically insufficient surgery; whenever TORS is offered as first-line therapy, one 
must reasonably expect that post-operative adjuvant therapy will either not be required 
or that the dose requirements will be significantly less than what is required for primary 
CRT. In the same way, when addressing the neck in TORS patients, nodal yield must be 
maximized while surgical morbidity minimized. 
 
In moving forwards, the role of TORS in the treatment spectrum of HNSCC must be 
considered in a geographical context. Being clearly less morbid than open surgery, 
TORS has rapidly gained field in the U.S. against primary CRT, the latter being the 
only other broadly accepted treatment. In Europe, where TOLM has long been widely 
established as a reasonable alternative to primary CRT, TORS has been slower to gain a 
foothold. However, as recognition of the technical advantages of TORS over TOLM 
increases, use of TORS in Europe will certainly expand. With time and competition, 
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economic barriers to the use of TORS will begin to decline. The HPV HNSCC 
epidemic disproportionately affecting younger and healthier patients will only serve to 
increase the use of the minimally invasive and function-conserving TORS approach 
when it allows for the reduction or elimination of the need for highly morbid CRT. 
 
Finally, if TORS is to succeed on a larger scale in the management of HNSCC, its 
current indications must be expanded. At present, the daVinci Surgical System is only 
approved for resection of T1 and T2 head and neck cancer; its use for the resection of 
larger or more invasive upper aero-digestive tract malignancies is strictly off-label, 
technically more challenging, and could be expected to result in more significant post-
operative functional impairment and complications. One possible means to expand the 
reach of TORS may be through the use of induction chemotherapy; T3 tumors that 
demonstrate a response might then become candidates for TORS. 
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6. CONCLUSIONS 
 
6.1. OPSCC 
 
Based upon our functional results and margin control rates, we found TORS to be an 
oncologically safe and technically feasible surgical modality. It widens our treatment 
portfolio by providing with a novel minimally invasive surgical alternative to select 
head and neck cancer patients, especially to those with T1 and T2 primary disease of the 
upper aerodigestive tract, with promising functional results. 
 
While it is difficult to assess components of the cumulative morbidity of combined 
treatment separately, it is of note that all patients with PEG-feeding did receive some 
form of adjuvant therapy, and none of the patients treated with surgery alone (TORS 
and neck dissection) needed PEG. One of the largest prospective, oropharyngeal post-
TORS quality of life studies [22] also showed TORS to be safe with excellent overall 
QoL and functional outcomes, even in patients undergoing adjuvant radiotherapy. In the 
latter group, after an initial drop in their post-treatment QoL-scores, overall QoL returns 
to baseline values by 12 months post-TORS. 
 
These seem to support our original premise that the overall morbidity of TORS and 
adjuvant therapy might be in well selected cases lower than the morbidity of primary 
chemoradiation. In the future, we think the emphasis of minimally invasive head and 
neck surgery will be shifted towards the HPV-driven patient population, which trend is 
not represented in our current set of data yet, but is to be certainly expected. 
 
Being TORS a relatively new technique worldwide, the number of studies presenting 
longer term results are still very limited. Based upon our early oncological and 
functional outcomes, we are convinced that further clinical investigations are justified 
and continued efforts to decrease the overall treatment-related morbidity of the 
multimodality therapy of head and neck squamous cell carcinoma are encouraged. In 
this scenario, TORS will most likely play an integral role as one of the leading 
modalities. 
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6.2. HPSCC 
 
From a functional point of you, numerous clinical studies have shown improved post-
TORS swallowing function compared to other surgical modalities and to primary 
chemoradiation therapy [91, 93], along with shorter hospital stay and faster recovery, as 
well as a more efficient return to work after completion of therapy [22, 78]. 
 
We found TORS to be an oncologically safe, technically feasible surgical modality for 
select T1 and T2 hypopharyngeal squamous cell carcinomas [80], with excellent margin 
control and minimal morbidity. Paired with an equally low-morbid selective neck 
dissection with sufficient nodal yield, the goal is to spare adjuvant treatment for a select 
group of low-risk patients. 
 
However, in cases where adjuvant therapy cannot be completely omitted, we find a 
reduction of at least 10-12 Gy in radiation (from 70-72 Gy of first-line conservative 
treatment to 60 Gy of adjuvant treatment) and sparing the chemotherapy component of 
adjuvant therapy, are worth indicating TORS and selective neck dissection for well 
accessible T1 and T2 hypopharyngeal carcinomas [80, 103], in order to improve their 
functional outcomes compared to first-line chemoradiotherapy [77, 79]. 
 
5.3. Neck Dissection 
 
Our study showed that a certain surgical concept and the standardised dissection 
technique derived from it, can deliver superior results in terms of nodal yield and may 
increase the overall oncological safety. It is remarkable that the horizontal technique, 
even as a freshly implemented method in this department, can produce reliably higher 
nodal yield values than the already well-established vertical technique. 
 
In an era of constantly growing health care costs, a simple change in the surgical 
mindset and dissection technique might contribute just as much to the oncological 
benefit of the patients as high-tech developments do, making a difference any surgeon 
can make without financial offset. 
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In conclusion, our study showed that the timing of the neck dissection in patients 
undergoing TORS does not have an impact on the outcomes. We still believe that neck 
dissections should be done as soon as possible following the TORS-procedure, ideally 
during the same session, as there is no reason to delay a neck dissection if it can be done 
on the same theatre list. On the other hand, appropriately indicated TORS-cases should 
not be restricted due to robotic slot and theatre time constraints, as TORS might be the 
ideal primary treatment option for a number of patients, even if the neck dissections 
cannot be done on the same day. In our experience, either way is feasible and leads to 
similar outcomes. 
 
5.4. TORS Concept 
 
As with any novel therapy, it is paramount that prospective multicenter randomized 
trials are able to confirm the safety and efficacy of TORS in the first-line management 
of HNSCC. These studies must be designed around the unique advantages and 
limitations of the daVinci Surgical System in TORS; proper patient selection within 
such studies is vital. We believe that the advantages offered by TORS over conventional 
treatment modalities applied on a wide scale will result in a paradigm shift in the QOL 
outcomes of head and neck cancer patients. However, further, higher level confirmatory 
evidence is needed for the growth of TORS in the management of HNSCC. 
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7. SUMMARY 
 
Background 
The multimodality treatment arsenal for head and neck squamous cell carcinoma has 
been recently supplemented by transoral robotic surgery (TORS). The purpose of this 
work was to introduce TORS and to define its role as part of the multidiscilpinary 
treatment spectrum of head and neck oncology, based on the author‟s clinical and 
surgical experience of over a hundred robotic cases, publications, as well as 
international teaching practice as a proctor and trainer in this regard. 
 
Methods 
TORS has been applied for the treatment of the primary tumours in the oropharynx and 
hypopharyx, while functional and selective neck dissections were used for the surgical 
treatment as well as for the staging of the regional lymph nodes in the neck, according 
to the approval of the institutional head and neck tumour board. 
 
Results 
So far the highest surgical monomodality treatment rates previously unmatched in the 
published literature, without adjuvant therapy. Comparable short-term (median, 2 years) 
oncological outcomes to that of primary chemoradiation, with improved functional 
results. First evidence for the impact of neck dissection surgical technique on the 
harvested nodal yield as an independent prognostic factor. First standardised, TNM-
stage relatedtreatment algorithm for the application of TORS in head and neck 
oncology. 
 
Conclusions 
TORS with functional and selective neck dissection and risk-adapted adjuvant therapy 
is able to match the oncologic outcomes of primary chemoradiation for T1 and T2 
HNSCC, possibly on a lower cost of treatment-related morbidity. 
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8. ÖSSZEFOGLALÁS 
 
Bevezetés 
A fej-nyaki rosszindulatú daganatok multidiszciplináris terápiás arzenálja a 
közelmúltban bővült a transzorális robotsebészet (TORS) nyújtotta lehetőségekkel. A 
disszertáció célja a fej-nyaki robotsebészet bemutatása és szerepének meghatározása a 
fej-nyaki onkológia multidiszciplináris terapiás spektrumának új tagjaként, a szerző 
saját ezirányú műtéti tapasztalatai (több mint 100 TORS-beavatkozás), publikációi és 
nemzetközi TORS-oktatói tapasztalatai alapján. 
 
Módszer 
TORS a primér tumor kezelésére (oropharynx és hypopharynx), funkcionális és 
szelektív nyaki blokkdisszekció a nyaki nyirokcsomók staging-je illetve sebészi 
terápiája céljából, s e két műtéttípus együttes alkalmazása az intézményi 
multidiszciplináris tumorboard előzetes jóváhagyása alapján. 
 
Eredmények 
Az eddigi irodalomban a legmagasabb arány adjuváns terápia nélkül, a primér 
kemoradioterápiával azonos rövid távú onkológiai, de annál dokumentáltan jobb 
funkcionális eredményekkel. Jól szelektált páciensek esetében a betegek túlnyomó 
többsége eredményesen kezelhető sebészi monomodalitás mellett.Először sikerült 
kimutatni, hogy a sebészi technika direkt módon hatással van a nyaki disszekció 
nyirokcsomó-hozamára, amely egy független prognosztikai faktor.Első ajánlás a TORS 
standardizált szerepére a fej-nyaki tumorok kezelésében, a cTNM-től függő algoritmus 
és terápiás protokoll kidolgozása révén. 
 
Következtetések 
A TORS, valamint a funkcionális és szelektív nyaki blokkdisszekció, rizikó-adaptált 
adjuváns sugárkezeléssel kiegészítve, képesek együttesen a primer kemoradiotarápiával 
egyenértű onkológiai, de annál jobb funkcionális erdeményeket szolgáltatni a T1-T2 
oropharyngeális rákok kezeléseben. 
 
DOI:10.14753/SE.2015.1766
 75 
9. REFERENCES 
 
 
[1] Weinstein GS, O'Malley BW. TransOral robotic surgery (TORS). 2012, San 
Diego, Plural Publishing. 
[2] Lorincz BB, Laban S, Knecht R. [The development of TORS in Europe]. 2013, 
HNO; 61:294-299. 
[3] Adelstein DJ, Ridge JA, Brizel DM, Holsinger FC, Haughey BH, O'Sullivan B, 
Genden EM, Beitler JJ, Weinstein GS, Quon H, Chepeha DB, Ferris RL, Weber RS, 
Movsas B, Waldron J, Lowe V, Ramsey S, Manola J, Yueh B, Carey TE, Bekelman JE, 
Konski AA, Moore E, Forastiere A, Schuller DE, Lynn J, Ullmann CD. Transoral 
resection of pharyngeal cancer: summary of a National Cancer Institute Head and 
Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 
2011, Arlington, Virginia. 2012, Head & Neck; 34:1681-1703. 
[4] Lohia S, Rajapurkar M, Nguyen SA, Sharma AK, Gillespie MB, Day TA. A 
comparison of outcomes using intensity-modulated radiation therapy and 3-
dimensional conformal radiation therapy in treatment of oropharyngeal cancer. 
2014,  JAMA Otolaryngology - Head & Neck Surgery; 140:331-337. 
[5] Grant DG, Salassa JR, Hinni ML, Pearson BW, Perry WC. Carcinoma of the 
tongue base treated by transoral laser microsurgery, part one: Untreated tumors, a 
prospective analysis of oncologic and functional outcomes. 2006, The 
Laryngoscope; 116:2150-2155. 
[6] Lorincz BB, Mockelmann N, Busch CJ, Knecht R. Functional Outcomes, 
Feasibility and Safety of Resection of Trans Oral Robotic Surgery (Tors): A Single-
Institution Series of Thirty-Five Consecutive Tors-Cases for Oropharyngeal 
Squamous Cell Carcinoma. 2014, Head & Neck (online). 
[7] Hashibe M, Sturgis EM. Epidemiology of oral-cavity and oropharyngeal 
carcinomas: controlling a tobacco epidemic while a human papillomavirus 
epidemic emerges. 2013, Otolaryngologic Clinics of North America; 46:507-520. 
 
 
 
DOI:10.14753/SE.2015.1766
 76 
[8] Nichols AC, Palma DA, Dhaliwal SS, Tan S, Theuer J, Chow W, Rajakumar C, Um 
S, Mundi N, Berk S, Zhou R, Basmaji J, Rizzo G, Franklin JH, Fung K, Kwan K, Wehrli 
B, Salvadori MI, Winquist E, Ernst S, Kuruvilla S, Read N, Venkatesan V, Todorovic 
B, Hammond JA, Koropatnick J, Mymryk JS, Yoo J, Barrett JW. The epidemic of 
human papillomavirus and oropharyngeal cancer in a Canadian population. 2013,  
Current Oncology; 20:212-219. 
[9] Ramqvist T, Dalianis T. Oropharyngeal cancer epidemic and human 
papillomavirus. 2010, Emerging Infectious Diseases; 16:1671-1677. 
[10] Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell 
carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of 
treatment and prevention. 2011, Anticancer Research; 31:1515-1519. 
[11] Bentzen SM, Rosenthal DI, Weymuller EA, Trotti A. Increasing toxicity in 
nonoperative head and neck cancer treatment: investigations and interventions. 
2007, International Journal of Radiation Oncology, Biology, Physics; 69:S79-82. 
[12] Maxwell JH, Mehta V, Wang H, Cunningham D, Duvvuri U, Kim S, Johnson J, 
Ferris RL. Quality of life in head and neck cancer patients: Impact of HPV and 
primary treatment modality. 2014, The Laryngoscope; 124:1592-1597. 
[13] Broglie MA, Soltermann A, Haile SR, Roosli C, Huber GF, Schmid S, Stoeckli SJ. 
Quality of life of oropharyngeal cancer patients with respect to treatment strategy 
and p16-positivity. 2013, The Laryngoscope; 123:164-170. 
[14] Grant DG, Hinni ML, Salassa JR, Perry WC, Hayden RE, Casler JD. 
Oropharyngeal cancer: a case for single modality treatment with transoral laser 
microsurgery. 2009, Archives of Otolaryngology - Head & Neck Surgery; 135:1225-
1230. 
[15] Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, Milov S, 
Lewis JS, Jr., Krishna M. Transoral laser microsurgery as primary treatment for 
advanced-stage oropharyngeal cancer: a United States multicenter study. 2011, 
Head & Neck; 33:1683-1694. 
[16] Lawson G, Matar N, Remacle M, Jamart J, Bachy V. Transoral robotic surgery 
for the management of head and neck tumors: learning curve. 2011, European 
Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of 
Oto-Rhino-Laryngological Societies; 268:1795-1801. 
DOI:10.14753/SE.2015.1766
 77 
[17] Cosmidis A, Rame JP, Dassonville O, Temam S, Massip F, Poissonnet G, Poupart 
M, Marandas P, De Raucourt D, Groupement d'Etudes des Tumeurs de la Tete et du 
C. T1-T2 NO oropharyngeal cancers treated with surgery alone. A GETTEC study. 
2004, European Archives of Oto-Rhino-Laryngology: Official Journal of the 
European Federation of Oto-Rhino-Laryngological Societies; 261:276-281. 
[18] Weinstein GS, O'Malley BW, Jr., Magnuson JS, Carroll WR, Olsen KD, Daio L, 
Moore EJ, Holsinger FC. Transoral robotic surgery: a multicenter study to assess 
feasibility, safety, and surgical margins. 2012, The Laryngoscope; 122:1701-1707. 
[19] Lamarre ED, Seth R, Lorenz RR, Esclamado R, Adelstein DJ, Rodriguez CP, 
Saxton J, Scharpf J. Intended single-modality management of T1 and T2 tonsillar 
carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a 
single institution. 2012, American Journal of Otolaryngology 2012; 33:98-103. 
[20] Moncrieff M, Sandilla J, Clark J, Clifford A, Shannon K, Gao K, O'Brien C. 
Outcomes of primary surgical treatment of T1 and T2 carcinomas of the 
oropharynx. 2009, The Laryngoscope; 119:307-311. 
[21] Richmon J, Quon H, Gourin CG. The effect of transoral robotic surgery on 
short-term outcomes and cost of care after oropharyngeal cancer surgery. 2013, 
The Laryngoscope (online). 
[22] Dziegielewski PT, Teknos TN, Durmus K, Old M, Agrawal A, Kakarala K, 
Marcinow A, Ozer E. Transoral robotic surgery for oropharyngeal cancer: long-
term quality of life and functional outcomes. 2013, JAMA Otolaryngology - Head & 
Neck Surgery; 139:1099-1108. 
[23] Weinstein GS, O'Malley BW, Jr., Snyder W, Hockstein NG. Transoral robotic 
surgery: supraglottic partial laryngectomy. 2007, The Annals of Otology, 
Rhinology, and Laryngology; 116:19-23. 
[24] Mendelsohn AH, Remacle M, Van Der Vorst S, Bachy V, Lawson G. Outcomes 
following transoral robotic surgery: supraglottic laryngectomy. 2013, The 
Laryngoscope; 123:208-214. 
 
 
 
DOI:10.14753/SE.2015.1766
 78 
[25] Lorincz BB, Busch CJ, Mockelmann N, Knecht R. Feasibility and safety of 
transoral robotic surgery (TORS) for early hypopharyngeal cancer: a subset 
analysis of the Hamburg University TORS-trial. 2014, European Archives of Oto-
Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-
Laryngological Societies 2014 (online). 
[26] Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, 
Haller DG. Colon cancer survival is associated with increasing number of lymph 
nodes analyzed: a secondary survey of intergroup trial INT-0089. 2013, Journal of 
Clinical Oncology: Official Journal of the American Society of Clinical Oncology; 
21:2912-2919. 
[27] Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for 
stages I to III of colon cancer: a population-based study. 2006, Annals of Surgery; 
244:602-610. 
[28] Cianchi F, Palomba A, Boddi V, Messerini L, Pucciani F, Perigli G, Bechi P, 
Cortesini C. Lymph node recovery from colorectal tumor specimens: 
recommendation for a minimum number of lymph nodes to be examined. 2002, 
World Journal of Surgery; 26:384-389. 
[29] Brunocilla E, Pernetti R, Schiavina R, Borghesi M, Vagnoni V, Rocca GC, 
Borgatti F, Concetti S, Martorana G. The number of nodes removed as well as the 
template of the dissection is independently correlated to cancer-specific survival 
after radical cystectomy for muscle-invasive bladder cancer. 2013, International 
Urology and Nephrology; 45:711-719. 
[30] Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of 
the number of lymph nodes retrieved on outcome in patients with muscle invasive 
bladder cancer. 2002, The Journal of Urology; 167:1295-1298. 
[31] Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and 
its impact on outcome in patients diagnosed with bladder cancer: analysis of data 
from the Surveillance, Epidemiology and End Results Program data base. 2003, 
The Journal of Urology; 169:946-950. 
 
 
 
DOI:10.14753/SE.2015.1766
 79 
[32] Briganti A, Chun FK, Salonia A, Gallina A, Zanni G, Scattoni V, Valiquette L, 
Rigatti P, Montorsi F, Karakiewicz PI. Critical assessment of ideal nodal yield at 
pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis 
in patients undergoing radical retropubic prostatectomy. 2007, Urology; 69:147-
151. 
[33] Johnson TV, Hsiao W, Delman KA, Jani AB, Brawley OW, Master VA. Extensive 
inguinal lymphadenectomy improves overall 5-year survival in penile cancer 
patients: results from the Surveillance, Epidemiology, and End Results program. 
2010, Cancer; 116:2960-2966. 
[34] Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Holscher 
A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR. The 
number of lymph nodes removed predicts survival in esophageal cancer: an 
international study on the impact of extent of surgical resection. 2008, Annals of 
Surgery; 248:549-556. 
[35] Volpe CM, Driscoll DL, Douglass HO, Jr. Outcome of patients with proximal 
gastric cancer depends on extent of resection and number of resected lymph 
nodes. 2000, Annals of Surgical Oncology; 7:139-144. 
[36] Weir L, Speers C, D'Yachkova Y, Olivotto IA. Prognostic significance of the 
number of axillary lymph nodes removed in patients with node-negative breast 
cancer. 2002, Journal of Clinical Oncology: Official Journal of the American Society 
of Clinical Oncology; 20:1793-1799. 
[37] Jaber JJ, Zender CA, Mehta V, Davis K, Ferris RL, Lavertu P, Rezaee R, Feustel 
PJ, Johnson JT. A multi-institutional investigation of the prognostic value of lymph 
nodal yield in advanced stage oral cavity squamous cell carcinoma (OCSCC). 2013, 
Head & Neck (online). 
[38] Pereira JA, Jimeno J, Miquel J, Iglesias M, Munne A, Sancho JJ, Sitges-Serra A. 
Nodal yield, morbidity, and recurrence after central neck dissection for papillary 
thyroid carcinoma. 2005, Surgery; 138:1095-1100, discussion 1100-1091. 
[39] Vas Nunes JH, Clark JR, Gao K, Chua E, Campbell P, Niles N, Gargya A, Elliott 
MS. Prognostic implications of lymph node yield and lymph node ratio in papillary 
thyroid carcinoma. 2013, Thyroid: Official Journal of the American Thyroid 
Association; 23:811-816. 
DOI:10.14753/SE.2015.1766
 80 
[40] Ebrahimi A, Zhang WJ, Gao K, Clark JR. Nodal yield and survival in oral 
squamous cancer: Defining the standard of care. 2011, Cancer; 117:2917-2925. 
[41] Patel SG, Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, 
Ebrahimi A, Clark JR, Cernea CR, Brandao SJ, Kreppel M, Zoller J, Fliss D, Fridman E, 
Bachar G, Shpitzer T, Bolzoni VA, Patel PR, Jonnalagadda S, Robbins KT, Shah JP, Gil 
Z. Lymph node density in oral cavity cancer: results of the International 
Consortium for Outcomes Research. 2013, British Journal of Cancer; 109:2087-
2095. 
[42] Agrama MT, Reiter D, Cunnane MF, Topham A, Keane WM. Nodal yield in neck 
dissection and the likelihood of metastases. 2003, Otolaryngology - Head and Neck 
Surgery: Official Journal of American Academy of Otolaryngology- Head and Neck 
Surgery; 128:185-190. 
[43] Ebrahimi A, Clark JR, Amit M, Yen TC, Liao CT, Kowalski LP, Kreppel M, Cernea 
CR, Bachar G, Villaret AB, Fliss D, Fridman E, Robbins KT, Shah JP, Patel SG, Gil Z. 
Minimum Nodal Yield in Oral Squamous Cell Carcinoma: Defining the Standard of 
Care in a Multicenter International Pooled Validation Study. 2014, Annals of 
Surgical Oncology (online). 
[44] Yu Y, Wang XL, Xu ZG, Li Q. [Prognostic value of the number of lymph nodes 
retrieved after selective neck dissection in hypopharyngeal squamous carcinoma]. 
2013, Chinese Journal of Otorhinolaryngology Head and Neck Surgery; 48:148-
153. 
[45] Norling R, Therkildsen MH, Bradley PJ, Nielsen MB, von Buchwald C. Nodal 
yield in selective neck dissection. 2013, Acta Oto-Laryngologica; 133:965-971. 
[46] Friedman M, Lim JW, Dickey W, Tanyeri H, Kirshenbaum GL, Phadke DM, 
Caldarelli D. Quantification of lymph nodes in selective neck dissection. 1999, The 
Laryngoscope; 109:368-370. 
[47] Morton RP, Gray L, Tandon DA, Izzard M, McIvor NP. Efficacy of neck 
dissection: are surgical volumes important? 2009, The Laryngoscope; 119:1147-
1152. 
[48] Upile T, Jerjes W, Nouraei SA, Singh S, Clarke P, Rhys-Evans P, Hopper C, 
Howard D, Wright A, Sudhoff H, Fisher C, Sandison A. How we do it: a method of 
neck dissection for histopathological analysis. 2007, BMC Surgery; 7:21. 
DOI:10.14753/SE.2015.1766
 81 
[49] Park YM, Kim WS, Byeon HK, De Virgilio A, Jung JS, Kim SH. Feasiblity of 
transoral robotic hypopharyngectomy for early-stage hypopharyngeal carcinoma. 
2010, Oral Oncology; 46:597-602. 
[50] Weinstein GS, O'Malley BW, Jr., Snyder W, Sherman E, Quon H. Transoral 
robotic surgery: radical tonsillectomy. 2007, Archives of Otolaryngology - Head & 
Neck Surgery; 133:1220-1226. 
[51] Weinstein GS, O'Malley BW, Jr., Cohen MA, Quon H. Transoral robotic surgery 
for advanced oropharyngeal carcinoma. 2010, Archives of Otolaryngology - Head & 
Neck Surgery; 136:1079-1085. 
[52] Moore EJ, Olsen KD, Martin EJ. Concurrent neck dissection and transoral 
robotic surgery. 2011, The Laryngoscope; 121:541-544. 
[53] Genden EM, Park R, Smith C, Kotz T. The role of reconstruction for transoral 
robotic pharyngectomy and concomitant neck dissection. 2011, Archives of 
Otolaryngology - Head & Neck Surgery; 137:151-156. 
[54] Howard BE, Hinni ML, Nagel TH, Chang YH, Cheng MR, Hayden RE. 
Submandibular gland preservation during concurrent neck dissection and 
transoral surgery for oropharyngeal squamous cell carcinoma. 2014, 
Otolaryngology - Head and Neck Surgery: Official Journal of American Academy of 
Otolaryngology- Head and Neck Surgery; 150:587-593. 
[55] Remacle M, Matar N, Lawson G, Bachy V. Laryngeal advanced retractor 
system: a new retractor for transoral robotic surgery. 2011, Otolaryngology - Head 
and Neck Surgery: Official Journal of American Academy of Otolaryngology- Head 
and Neck Surgery; 145:694-696. 
[56] Quon H, Cohen MA, Montone KT, Ziober AF, Wang LP, Weinstein GS, O'Malley 
BW, Jr. Transoral robotic surgery and adjuvant therapy for oropharyngeal 
carcinomas and the influence of p16 INK4a on treatment outcomes. 2013, The 
Laryngoscope; 123:635-640. 
[57] Quon H, O'Malley BW, Jr., Weinstein GS. Postoperative adjuvant therapy after 
transoral robotic resection for oropharyngeal carcinomas: rationale and current 
treatment approach. 2011, ORL: Journal for Oto-Rhino-Laryngology and its Related 
Specialties; 73:121-130. 
DOI:10.14753/SE.2015.1766
 82 
[58] Weinstein GS, Quon H, O'Malley BW, Jr., Kim GG, Cohen MA. Selective neck 
dissection and deintensified postoperative radiation and chemotherapy for 
oropharyngeal cancer: a subset analysis of the University of Pennsylvania 
transoral robotic surgery trial. 2010, The Laryngoscope; 120:1749-1755. 
[59] Weinstein GS, Quon H, Newman HJ, Chalian JA, Malloy K, Lin A, Desai A, Livolsi 
VA, Montone KT, Cohen KR, O'Malley BW. Transoral robotic surgery alone for 
oropharyngeal cancer: an analysis of local control. 2012, Archives of 
Otolaryngology- Head & Neck Surgery; 138:628-634. 
[60] O'Malley BW, Jr., Weinstein GS, Snyder W, Hockstein NG. Transoral robotic 
surgery (TORS) for base of tongue neoplasms. 2006, The Laryngoscope; 116:1465-
1472. 
[61] Chi JJ, Mandel JE, Weinstein GS, O'Malley BW, Jr. Anesthetic considerations for 
transoral robotic surgery. 2010, Anesthesiology Clinics; 28:411-422. 
[62] Hockstein NG, Weinstein GS, O'Malley Jr BW. Maintenance of hemostasis in 
transoral robotic surgery. 2005, ORL: Journal for Oto-Rhino-Laryngology and its 
Related Specialties; 67:220-224. 
[63] Hockstein NG, O'Malley BW, Jr., Weinstein GS. Assessment of intraoperative 
safety in transoral robotic surgery. 2006, The Laryngoscope; 116:165-168. 
[64] Lawson G, Mendelsohn AH, Van Der Vorst S, Bachy V, Remacle M. Transoral 
robotic surgery total laryngectomy. 2013, The Laryngoscope; 123:193-196. 
[65] Bhattacharyya N. The effects of more conservative neck dissections and 
radiotherapy on nodal yields from the neck. 1998, Archives of Otolaryngology - 
Head & Neck Surgery; 124:412-416. 
[66] Gavilán J. Functional and selective neck dissection. 2002, New York, Thieme; 
pp. xiv, 161 p. 
[67] Ferlito A, Gavilan J, Buckley JG, Shaha AR, Miodonski AJ, Rinaldo A. Functional 
neck dissection: Fact and fiction. 2011, Head & Neck; 23:804-808. 
[68] Kerawala CJ, Bisase B, Hopper A. Is total nodal yield in neck dissections 
influenced by the method of specimen presentation to the pathologist? 2009, The 
British Journal of Oral & Maxillofacial Surgery; 47:360-362. 
 
DOI:10.14753/SE.2015.1766
 83 
[69] Ferlito A, Rinaldo A, Silver CE, Shah JP, Suarez C, Medina JE, Kowalski LP, 
Johnson JT, Strome M, Rodrigo JP, Werner JA, Takes RP, Towpik E, Robbins KT, 
Leemans CR, Herranz J, Gavilan J, Shaha AR, Wei WI. Neck dissection: then and 
now. 2006, Auris, Nasus, Larynx; 33:365-374. 
[70] Gavilan J, Gavilan C, Herranz J. Functional neck dissection: three decades of 
controversy. 1992, The Annals of Otology, Rhinology, and Laryngology; 101:339-
341. 
[71] Gavilan C, Gavilan J. Five-year results of functional neck dissection for cancer 
of the larynx. 1989, Archives of Otolaryngology - Head & Neck Surgery; 115:1193-
1196. 
[72] Patel RS, Clark JR, Gao K, O'Brien CJ. Effectiveness of selective neck dissection 
in the treatment of the clinically positive neck. 2008, Head & Neck; 30:1231-1236. 
[73] Url C, Schartinger VH, Riechelmann H, Gluckert R, Maier H, Trumpp M, 
Widmann G. Radiological detection of extracapsular spread in head and neck 
squamous cell carcinoma (HNSCC) cervical metastases. 2013, European Journal of 
Radiology; 82:1783-1787. 
[74] Zoumalan RA, Kleinberger AJ, Morris LG, Ranade A, Yee H, DeLacure MD, 
Myssiorek D. Lymph node central necrosis on computed tomography as predictor 
of extracapsular spread in metastatic head and neck squamous cell carcinoma: 
pilot study. 2010, The Journal of Laryngology and Otology; 124:1284-1288. 
[75] Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J. Three-dimensional conformal 
vs. intensity-modulated radiotherapy in head-and-neck cancer patients: 
comparative analysis of dosimetric and technical parameters. 2004, International 
Journal of Radiation Oncology, Biology, Physics; 58:617-624. 
[76] Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison 
W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-
term results of RTOG 91-11: a comparison of three nonsurgical treatment 
strategies to preserve the larynx in patients with locally advanced larynx cancer. 
2013, Journal of Clinical Oncology: Official Journal of the American Society of 
Clinical Oncology; 31:845-852. 
 
 
DOI:10.14753/SE.2015.1766
 84 
[77] Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ, Karlsson U, Dutta S, Midyett 
FA, Barloon J, Sallah S. Dysphagia following chemoradiation for locally advanced 
head and neck cancer. 2004, Annals of Oncology: Official Journal of the European 
Society for Medical Oncology (ESMO); 15:383-388. 
[78] Iseli TA, Kulbersh BD, Iseli CE, Carroll WR, Rosenthal EL, Magnuson JS. 
Functional outcomes after transoral robotic surgery for head and neck cancer. 
2009, Otolaryngology - Head and Neck Surgery: Official Journal of American 
Academy of Otolaryngology- Head and Neck Surgery; 141:166-171. 
[79] More YI, Tsue TT, Girod DA, Harbison J, Sykes KJ, Williams C, Shnayder Y. 
Functional swallowing outcomes following transoral robotic surgery vs primary 
chemoradiotherapy in patients with advanced-stage oropharynx and supraglottis 
cancers. 2013, JAMA Otolaryngology - Head &Neck Surgery; 139:43-48. 
[80] Park YM, Kim WS, De Virgilio A, Lee SY, Seol JH, Kim SH. Transoral robotic 
surgery for hypopharyngeal squamous cell carcinoma: 3-year oncologic and 
functional analysis. 2012, Oral Oncology; 48:560-566. 
[81] Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated 
cervical carcinogenesis. 2005, Cancer Research and Treatment: Official Journal of 
the Korean Cancer Association; 37:319-324. 
[82] Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, 
Wakely P, Xiao W, Gillison ML. Validation of methods for oropharyngeal cancer 
HPV status determination in US cooperative group trials. 2012, The American 
Journal of Surgical Pathology; 36:945-954. 
[83] Barten M, Ostwald C, Milde-Langosch K, Muller P, Wukasch Y, Loning T. HPV 
DNA and p53 alterations in oropharyngeal carcinomas. 1995, Virchows Archiv: an 
International Journal of Pathology; 427:153-157. 
[84] Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba 
SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, 
Kurnit DM, Bauer JA, Bradford CR, Carey TE. EGFR, p16, HPV Titer, Bcl-xL and p53, 
sex, and smoking as indicators of response to therapy and survival in 
oropharyngeal cancer. 2008, Journal of Clinical Oncology: Official Journal of the 
American Society of Clinical Oncology; 26:3128-3137. 
DOI:10.14753/SE.2015.1766
 85 
[85] Worsham MJ, Stephen JK, Chen KM, Mahan M, Schweitzer V, Havard S, Divine 
G. Improved survival with HPV among African Americans with oropharyngeal 
cancer. 2013, Clinical Cancer Research: an Official Journal of the American 
Association for Cancer Research; 19:2486-2492. 
[86] Ampil F, Chaudhery S, Devarakonda S, Mills G. Extended survival after 
chemotherapy and conservative radiotherapy for HPV-16 positive stage IVB 
oropharyngeal carcinoma. 2013, Acta Oncologica; 52:1236-1237. 
[87] Lill C, Kornek G, Bachtiary B, Selzer E, Schopper C, Mittlboeck M, Burian M, 
Wrba F, Thurnher D. Survival of patients with HPV-positive oropharyngeal cancer 
after radiochemotherapy is significantly enhanced. 2011, Wiener Klinische 
Wochenschrift; 123:215-221. 
[88] Genden EM. The role for surgical management of HPV-related oropharyngeal 
carcinoma. 2012, Head and Neck Pathology; 6 Suppl 1:S98-103. 
[89] Leonhardt FD, Quon H, Abrahao M, O'Malley BW, Jr., Weinstein GS. Transoral 
robotic surgery for oropharyngeal carcinoma and its impact on patient-reported 
quality of life and function. 2012, Head & Neck; 34:146-154. 
[90] Genden EM, O'Malley BW, Jr., Weinstein GS, Stucken CL, Selber JC, Rinaldo A, 
Hockstein NG, Ozer E, Mallet Y, Satava RM, Moore EJ, Silver CE, Ferlito A. Transoral 
robotic surgery: role in the management of upper aerodigestive tract tumors. 
2012, Head & Neck; 34:886-893. 
[91] Sinclair CF, McColloch NL, Carroll WR, Rosenthal EL, Desmond RA, Magnuson 
JS. Patient-perceived and objective functional outcomes following transoral robotic 
surgery for early oropharyngeal carcinoma. 2011, Archives of Otolaryngology - 
Head & Neck Surgery; 137:1112-1116. 
[92] Hans S, Jouffroy T, Veivers D, Hoffman C, Girod A, Badoual C, Rodriguez J, 
Brasnu D. Transoral robotic-assisted free flap reconstruction after radiation 
therapy in hypopharyngeal carcinoma: report of two cases. 2013, European 
Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of 
Oto-Rhino-Laryngological Societies; 270:2359-2364. 
[93] Richmon JD, Quon H, Gourin CG. The effect of transoral robotic surgery on 
short-term outcomes and cost of care after oropharyngeal cancer surgery. 2014, 
The Laryngoscope; 124:165-171. 
DOI:10.14753/SE.2015.1766
 86 
[94] Kofler B, Laban S, Busch CJ, Lorincz B, Knecht R. New treatment strategies for 
HPV-positive head and neck cancer. 2014, European Archives of Oto-Rhino-
Laryngology: Official Journal of the European Federation of Oto-Rhino-
Laryngological Societies; 271:1861-1867. 
[95] Cohen MA, Weinstein GS, O'Malley BW, Jr., Feldman M, Quon H. Transoral 
robotic surgery and human papillomavirus status: Oncologic results. 2011, Head & 
Neck; 33:573-580. 
[96] Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A, Tornillo L, 
Wolfensberger M, Terracciano LM. Is the improved prognosis of p16 positive 
oropharyngeal squamous cell carcinoma dependent of the treatment modality? 
2010, International Journal of Cancer; 126:1256-1262. 
[97] Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini 
C, Cantu G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, 
Pilotti S. High-risk human papillomavirus affects prognosis in patients with 
surgically treated oropharyngeal squamous cell carcinoma. 2006, Journal of 
Clinical Oncology: Official Journal of the American Society of Clinical Oncology; 
24:5630-5636. 
[98] Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, Clark JR, 
Milross CG, Kim J, O'Brien CJ, Rose BR. Human papillomavirus predicts outcome in 
oropharyngeal cancer in patients treated primarily with surgery or radiation 
therapy. 2010, British Journal of Cancer; 103:1510-1517. 
[99] Salazar CR, Smith RV, Garg MK, Haigentz M, Jr., Schiff BA, Kawachi N, 
Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. Human 
Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Survival: A 
Comparison by Tumor Site and Initial Treatment. 2013, Head and Neck Pathology 
(online). 
[100] Lassaletta L, Garcia-Pallares M, Morera E, Salinas S, Bernaldez R, Patron M, 
Gavilan J. Functional neck dissection for the clinically negative neck: effectiveness 
and controversies. 2002, The Annals of Otology, Rhinology, and Laryngology; 
111:169-173. 
 
DOI:10.14753/SE.2015.1766
 87 
[101] Nichols AC, Yoo J, Hammond JA, Fung K, Winquist E, Read N, Venkatesan V, 
MacNeil SD, Ernst DS, Kuruvilla S, Chen J, Corsten M, Odell M, Eapen L, Theurer J, 
Doyle PC, Wehrli B, Kwan K, Palma DA. Early-stage squamous cell carcinoma of the 
oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) -study protocol 
for a randomized phase II trial. 2013, BMC Cancer; 13:133. 
[102] Kunzel J, Psychogios G, Mantsopoulos K, Grundtner P, Waldfahrer F, Iro H. 
Lymph node ratio as a predictor of outcome in patients with oropharyngeal cancer. 
2013, European Archives of Oto-Rhino-Laryngology: Official Journal of the 
European Federation of Oto-Rhino-Laryngological Societies (online). 
[103] Quon H, Richmon JD. Treatment deintensification strategies for HPV-
associated head and neck carcinomas. 2012, Otolaryngologic Clinics of North 
America; 45:845-861. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DOI:10.14753/SE.2015.1766
 88 
10. PUBLICATIONS 
 
10.1.  Related to the Ph.D. Thesis 
 
1. Lorincz BB, Mockelmann N, Busch CJ, Knecht R. Functional outcomes, feasibility, 
and safety of resection of transoral robotic surgery: Single-institution series of 35 
consecutive cases of transoral robotic surgery for oropharyngeal squamous cell 
carcinoma. 2014, Head & Neck (online). 
 
2. Lorincz BB, Busch CJ, Mockelmann N, Knecht R. Feasibility and safety of transoral 
robotic surgery (TORS) for early hypopharyngeal cancer: a subset analysis of the 
Hamburg University TORS-trial. 2014, European Archives of Oto-Rhino-Laryngology: 
Official Journal of the European Federation of Oto-Rhino-Laryngological Societies 
(online). 
 
3. Lorincz BB, Knecht R. [Transoral robotic total laryngectomy and neck dissection: the 
concept of robotic combo surgery]. 2013, Laryngo-Rhino-Otologie; 92:585-588. 
 
4. Lorincz BB, Laban S, Knecht R. [The development of TORS in Europe]. 2013, 
HNO; 61:294-299. 
 
10.2.  Other Publications 
 
5. Lorincz BB, Mockelmann N, Knecht R. Single-incision transaxillary robotic total 
thyroidectomy for Graves' disease: improved feasibility and safety with novel robotic 
instrumentation. 2014, European Archives of Oto-Rhino-Laryngology: Official Journal 
of the European Federation of Oto-Rhino-Laryngological Societies (online). 
 
6. Kofler B, Laban S, Busch CJ, Lorincz B, Knecht R. New treatment strategies for 
HPV-positive head and neck cancer. 2014, European Archives of Oto-Rhino-
Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological 
Societies; 271:1861-1867. 
DOI:10.14753/SE.2015.1766
 89 
 
7. Jowett N, Wöllmer W, Reimer R, Zustin J, Schumacher U, Wiseman PW, Mlynarek 
AM, Böttcher A, Dalchow CV, Lörincz BB, Knecht R, Miller RJ.Bone ablation without 
thermal or acoustic mechanical injury via a novel picosecond infrared laser (PIRL). 
2014, Otolaryngology - Head and Neck Surgery: Official Journal of American 
Academy of Otolaryngology- Head and Neck Surgery; 150:385-393. 
 
8. Lorincz BB, Mandapathil M. [Robot-assisted transoral tumor surgery possible]. 2013, 
Laryngo-Rhino-Otologie; 92:642-643. 
 
9. Bottcher A, Knecht R, Busch CJ, Lörincz BB, Dalchow CV. [Hereditary 
sensorineural hearing impairment and macrothrombocytopenia: a rare MYH9 gene 
mutation]. 2013, HNO; 61:159-160, 162-155. 
 
10. Ebrahimi A, Clark JR, Lorincz BB, Milross CG, Veness MJ. Metastatic head and 
neck cutaneous squamous cell carcinoma: defining a low-risk patient. 2012, Head & 
Neck; 34:365-370. 
 
11. Peters P, Stark P, Essig G Jr, Lorincz B, Bowman J, Tran K, Coman S. Lingual 
thyroid: an unusual and surgically curable cause of sleep apnoea in a male. 2010, Sleep 
& Breathing = Schlaf & Atmung; 14:377-380. 
 
12. Lorincz BB, Kalman E, Gerlinger I. KTP-532 laser-assisted microvascular 
anastomosis (experimental animal study). 2007, European Archives of Oto-Rhino-
Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological 
Societies; 264:823-828. 
 
13. Lorincz BB, Lichtenberger G, Bihari A, Falvai J. Therapy of periprosthetical 
leakage with tissue augmentation using Bioplastique around the implanted voice 
prosthesis. 2005, European Archives of Oto-Rhino-Laryngology: Official Journal of the 
European Federation of Oto-Rhino-Laryngological Societies; 262:32-34. 
 
DOI:10.14753/SE.2015.1766
 90 
 
11. ACKNOWLEDGEMENTS 
 
Katalin Hutter, Oliver Lörincz, György Lörincz Jr., Katalin Lörincz, György Lörincz 
Sr., Aranka Török, Borbála Lörincz, Hilda Kobia, Ferenc Gallyas, Imre Gerlinger, 
+György Lichtenberger, Károly Polus, Jan Olofsson, William Coman, Chris Perry, 
+Frank Szallasi, Chris O‟Brien, Jonathan Clark, Kerwin Shannon, Ardalan Ebrahimi, 
Suren Krishnan, Theo Gregor, Rainald Knecht, Nikolaus Möckelmann, Chia-Jung 
Busch, Nathan Jowett, Geza Jako, György Weber, Georges Lawson, Marc Remacle, 
Gregory Weinstein, Neil Tolley, Asit Arora, Kyung Tae, Micaela Piccoli, Tiziana 
Bonciani, Sabine Pohlmann, Javier Gavilan and K. Thomas Robbins. 
 
 
DOI:10.14753/SE.2015.1766
